{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T04:54:37Z","timestamp":1794200077363,"version":"4.8.0"},"reference-count":465,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-024-01621-x","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T06:03:24Z","timestamp":1730959404000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms"],"prefix":"10.1186","volume":"17","author":[{"given":"Yijun","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"1621_CR1","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood.2018894618","volume":"133","author":"P La Ros\u00e9e","year":"2019","unstructured":"La Ros\u00e9e P, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133:2465\u201377. https:\/\/doi.org\/10.1182\/blood.2018894618.","journal-title":"Blood"},{"key":"1621_CR2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S0140-6736(00)61951-7","volume":"234","author":"RB Scott","year":"1939","unstructured":"Scott RB, Robb-Smith A. Histiocytic medullary reticulosis. The Lancet. 1939;234:194\u20138.","journal-title":"The Lancet"},{"key":"1621_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1136\/adc.27.136.519","volume":"27","author":"JW Farquhar","year":"1952","unstructured":"Farquhar JW, Claireaux AE. Familial haemophagocytic reticulosis. Arch Dis Child. 1952;27:519\u201325. https:\/\/doi.org\/10.1136\/adc.27.136.519.","journal-title":"Arch Dis Child"},{"key":"1621_CR4","doi-asserted-by":"publisher","first-page":"1210041","DOI":"10.3389\/fimmu.2023.1210041","volume":"14","author":"A Chinnici","year":"2023","unstructured":"Chinnici A, et al. Approaching hemophagocytic lymphohistiocytosis. Front Immunol. 2023;14:1210041. https:\/\/doi.org\/10.3389\/fimmu.2023.1210041.","journal-title":"Front Immunol"},{"key":"1621_CR5","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1126\/science.286.5446.1957","volume":"286","author":"SE Stepp","year":"1999","unstructured":"Stepp SE, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999;286:1957\u20139. https:\/\/doi.org\/10.1126\/science.286.5446.1957.","journal-title":"Science"},{"key":"1621_CR6","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/26683","volume":"395","author":"J Sayos","year":"1998","unstructured":"Sayos J, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature. 1998;395:462\u20139. https:\/\/doi.org\/10.1038\/26683.","journal-title":"Nature"},{"key":"1621_CR7","doi-asserted-by":"publisher","first-page":"13765","DOI":"10.1073\/pnas.95.23.13765","volume":"95","author":"KE Nichols","year":"1998","unstructured":"Nichols KE, et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A. 1998;95:13765\u201370. https:\/\/doi.org\/10.1073\/pnas.95.23.13765.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1621_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/2424","volume":"20","author":"AJ Coffey","year":"1998","unstructured":"Coffey AJ, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet. 1998;20:129\u201335. https:\/\/doi.org\/10.1038\/2424.","journal-title":"Nat Genet"},{"key":"1621_CR9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/382262a0","volume":"382","author":"MD Barbosa","year":"1996","unstructured":"Barbosa MD, et al. Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature. 1996;382:262\u20135. https:\/\/doi.org\/10.1038\/382262a0.","journal-title":"Nature"},{"key":"1621_CR10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/art.40417","volume":"70","author":"RE Borgia","year":"2018","unstructured":"Borgia RE, Gerstein M, Levy DM, Silverman ED, Hiraki LT. Features, treatment, and outcomes of macrophage activation syndrome in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol. 2018;70:616\u201324. https:\/\/doi.org\/10.1002\/art.40417.","journal-title":"Arthritis Rheumatol"},{"key":"1621_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/mph.0000000000000872","volume":"39","author":"S Garc\u00eda-Pav\u00f3n","year":"2017","unstructured":"Garc\u00eda-Pav\u00f3n S, Yamazaki-Nakashimada MA, B\u00e1ez M, Borjas-Aguilar KL, Murata C. Kawasaki disease complicated with macrophage activation syndrome: a systematic review. J Pediatr Hematol Oncol. 2017;39:445\u201351. https:\/\/doi.org\/10.1097\/mph.0000000000000872.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1621_CR12","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1136\/ard.2005.046904","volume":"65","author":"JB Arlet","year":"2006","unstructured":"Arlet JB, et al. Reactive haemophagocytic syndrome in adult-onset Still\u2019s disease: a report of six patients and a review of the literature. Ann Rheum Dis. 2006;65:1596\u2013601. https:\/\/doi.org\/10.1136\/ard.2005.046904.","journal-title":"Ann Rheum Dis"},{"key":"1621_CR13","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/s0022-3476(96)70140-3","volume":"129","author":"AA Grom","year":"1996","unstructured":"Grom AA, Passo M. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr. 1996;129:630\u20132. https:\/\/doi.org\/10.1016\/s0022-3476(96)70140-3.","journal-title":"J Pediatr"},{"key":"1621_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41375-024-02135-8","volume":"38","author":"J Knauft","year":"2024","unstructured":"Knauft J, et al. Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis. Leukemia. 2024;38:235\u201349. https:\/\/doi.org\/10.1038\/s41375-024-02135-8.","journal-title":"Leukemia"},{"key":"1621_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13045-023-01434-4","volume":"16","author":"J West","year":"2023","unstructured":"West J, et al. 1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003\u20132018. J Hematol Oncol. 2023;16:56. https:\/\/doi.org\/10.1186\/s13045-023-01434-4.","journal-title":"J Hematol Oncol"},{"key":"1621_CR16","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1182\/blood-2011-06-356261","volume":"118","author":"H Trottestam","year":"2011","unstructured":"Trottestam H, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118:4577\u201384. https:\/\/doi.org\/10.1182\/blood-2011-06-356261.","journal-title":"Blood"},{"key":"1621_CR17","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","volume":"100","author":"JI Henter","year":"2002","unstructured":"Henter JI, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100:2367\u201373. https:\/\/doi.org\/10.1182\/blood-2002-01-0172.","journal-title":"Blood"},{"key":"1621_CR18","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","volume":"382","author":"F Locatelli","year":"2020","unstructured":"Locatelli F, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020;382:1811\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1911326.","journal-title":"N Engl J Med"},{"key":"1621_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-018-0653-x","volume":"11","author":"D Liu","year":"2018","unstructured":"Liu D, Zhao J. Cytokine release syndrome: grading, modeling, and new therapy. J Hematol Oncol. 2018;11:121. https:\/\/doi.org\/10.1186\/s13045-018-0653-x.","journal-title":"J Hematol Oncol"},{"key":"1621_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-020-00171-5","volume":"9","author":"Z Hao","year":"2020","unstructured":"Hao Z, Li R, Meng L, Han Z, Hong Z. Macrophage, the potential key mediator in CAR-T related CRS. Exp Hematol Oncol. 2020;9:15. https:\/\/doi.org\/10.1186\/s40164-020-00171-5.","journal-title":"Exp Hematol Oncol"},{"key":"1621_CR21","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s12276-024-01182-6","volume":"56","author":"TTT Nguyen","year":"2024","unstructured":"Nguyen TTT, Kim YT, Jeong G, Jin M. Immunopathology of and potential therapeutics for secondary hemophagocytic lymphohistiocytosis\/macrophage activation syndrome: a translational perspective. Exp Mol Med. 2024;56:559\u201369. https:\/\/doi.org\/10.1038\/s12276-024-01182-6.","journal-title":"Exp Mol Med"},{"key":"1621_CR22","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nri2803","volume":"10","author":"G de Saint Basile","year":"2010","unstructured":"de Saint Basile G, M\u00e9nasch\u00e9 G, Fischer A. Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nat Rev Immunol. 2010;10:568\u201379. https:\/\/doi.org\/10.1038\/nri2803.","journal-title":"Nat Rev Immunol"},{"key":"1621_CR23","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1242\/jcs.186205","volume":"129","author":"NM Dieckmann","year":"2016","unstructured":"Dieckmann NM, Frazer GL, Asano Y, Stinchcombe JC, Griffiths GM. The cytotoxic T lymphocyte immune synapse at a glance. J Cell Sci. 2016;129:2881\u20136. https:\/\/doi.org\/10.1242\/jcs.186205.","journal-title":"J Cell Sci"},{"key":"1621_CR24","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/s1074-7613(01)00234-5","volume":"15","author":"JC Stinchcombe","year":"2001","unstructured":"Stinchcombe JC, Bossi G, Booth S, Griffiths GM. The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity. 2001;15:751\u201361. https:\/\/doi.org\/10.1016\/s1074-7613(01)00234-5.","journal-title":"Immunity"},{"key":"1621_CR25","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/nri1983","volume":"6","author":"I Voskoboinik","year":"2006","unstructured":"Voskoboinik I, Smyth MJ, Trapani JA. Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol. 2006;6:940\u201352. https:\/\/doi.org\/10.1038\/nri1983.","journal-title":"Nat Rev Immunol"},{"key":"1621_CR26","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1182\/blood.2019000936","volume":"135","author":"SW Canna","year":"2020","unstructured":"Canna SW, Marsh RA. Pediatric hemophagocytic lymphohistiocytosis. Blood. 2020;135:1332\u201343. https:\/\/doi.org\/10.1182\/blood.2019000936.","journal-title":"Blood"},{"key":"1621_CR27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1084\/jem.20140964","volume":"212","author":"MR Jenkins","year":"2015","unstructured":"Jenkins MR, et al. Failed CTL\/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. J Exp Med. 2015;212:307\u201317. https:\/\/doi.org\/10.1084\/jem.20140964.","journal-title":"J Exp Med"},{"key":"1621_CR28","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3389\/fimmu.2013.00448","volume":"4","author":"B Jessen","year":"2013","unstructured":"Jessen B, et al. Graded defects in cytotoxicity determine severity of hemophagocytic lymphohistiocytosis in humans and mice. Front Immunol. 2013;4:448. https:\/\/doi.org\/10.3389\/fimmu.2013.00448.","journal-title":"Front Immunol"},{"key":"1621_CR29","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s12026-022-09285-w","volume":"70","author":"HQ Zhang","year":"2022","unstructured":"Zhang HQ, et al. Cytokine storm and targeted therapy in hemophagocytic lymphohistiocytosis. Immunol Res. 2022;70:566\u201377. https:\/\/doi.org\/10.1007\/s12026-022-09285-w.","journal-title":"Immunol Res"},{"key":"1621_CR30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0092-8674(03)00855-9","volume":"115","author":"J Feldmann","year":"2003","unstructured":"Feldmann J, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003;115:461\u201373.","journal-title":"Cell"},{"key":"1621_CR31","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/hmg\/ddi076","volume":"14","author":"U zur Stadt","year":"2005","unstructured":"zur Stadt U, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet. 2005;14:827\u201334.","journal-title":"Hum Mol Genet"},{"key":"1621_CR32","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ajhg.2009.09.005","volume":"85","author":"U Zur Stadt","year":"2009","unstructured":"Zur Stadt U, et al. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18\u20132 and impaired binding to syntaxin 11. Am J Hum Genet. 2009;85:482\u201392.","journal-title":"Am J Hum Genet"},{"key":"1621_CR33","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1182\/blood.v97.4.1131","volume":"97","author":"M Arico","year":"2001","unstructured":"Arico M, et al. Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene. Blood. 2001;97:1131\u20133. https:\/\/doi.org\/10.1182\/blood.v97.4.1131.","journal-title":"Blood"},{"key":"1621_CR34","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature05257","volume":"444","author":"S Rigaud","year":"2006","unstructured":"Rigaud S, et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature. 2006;444:110\u20134. https:\/\/doi.org\/10.1038\/nature05257.","journal-title":"Nature"},{"key":"1621_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/hon.2900040405","volume":"4","author":"J Goldberg","year":"1986","unstructured":"Goldberg J, Nezelof C. Lymphohistiocytosis: a multi-factorial syndrome of macrophagic activation clinico-pathological study of 38 cases. Hematol Oncol. 1986;4:275\u201389. https:\/\/doi.org\/10.1002\/hon.2900040405.","journal-title":"Hematol Oncol"},{"key":"1621_CR36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1182\/blood-2005-11-4413","volume":"108","author":"A Enders","year":"2006","unstructured":"Enders A, et al. Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II. Blood. 2006;108:81\u20137.","journal-title":"Blood"},{"key":"1621_CR37","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1046\/j.1365-2141.2000.01923.x","volume":"108","author":"E Grunebaum","year":"2000","unstructured":"Grunebaum E, Zhang J, Dadi H, Roifman CM. Haemophagocytic lymphohistiocytosis in X-linked severe combined immunodeficiency. Br J Haematol. 2000;108:834\u20137. https:\/\/doi.org\/10.1046\/j.1365-2141.2000.01923.x.","journal-title":"Br J Haematol"},{"key":"1621_CR38","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1080\/08035250310003631","volume":"92","author":"S Pasic","year":"2003","unstructured":"Pasic S, Micic D, Kuzmanovic M. Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis in Wiskott-Aldrich syndrome. Acta Paediatr. 2003;92:859\u201361. https:\/\/doi.org\/10.1080\/08035250310003631.","journal-title":"Acta Paediatr"},{"key":"1621_CR39","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1099\/jmm.0.47071-0","volume":"56","author":"M Hisano","year":"2007","unstructured":"Hisano M, et al. Bacteria-associated haemophagocytic syndrome and septic pulmonary embolism caused by Burkholderia cepacia complex in a woman with chronic granulomatous disease. J Med Microbiol. 2007;56:702\u20135. https:\/\/doi.org\/10.1099\/jmm.0.47071-0.","journal-title":"J Med Microbiol"},{"key":"1621_CR40","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/pbc.21573","volume":"51","author":"KA Schultz","year":"2008","unstructured":"Schultz KA, et al. Familial hemophagocytic lymphohistiocytosis in two brothers with X-linked agammaglobulinemia. Pediatr Blood Cancer. 2008;51:293\u20135. https:\/\/doi.org\/10.1002\/pbc.21573.","journal-title":"Pediatr Blood Cancer"},{"key":"1621_CR41","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1172\/jci37901","volume":"119","author":"K Huck","year":"2009","unstructured":"Huck K, et al. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest. 2009;119:1350\u20138. https:\/\/doi.org\/10.1172\/jci37901.","journal-title":"J Clin Invest"},{"key":"1621_CR42","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.jaci.2011.01.046","volume":"127","author":"TW Kuijpers","year":"2011","unstructured":"Kuijpers TW, et al. Common variable immunodeficiency and hemophagocytic features associated with a FAS gene mutation. J Allergy Clin Immunol. 2011;127:1411-1414.e1412. https:\/\/doi.org\/10.1016\/j.jaci.2011.01.046.","journal-title":"J Allergy Clin Immunol"},{"key":"1621_CR43","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/ng.3089","volume":"46","author":"SW Canna","year":"2014","unstructured":"Canna SW, et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet. 2014;46:1140\u20136. https:\/\/doi.org\/10.1038\/ng.3089.","journal-title":"Nat Genet"},{"key":"1621_CR44","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.jaci.2015.02.022","volume":"136","author":"OK Alkhairy","year":"2015","unstructured":"Alkhairy OK, et al. Novel mutations in TNFRSF7\/CD27: Clinical, immunologic, and genetic characterization of human CD27 deficiency. J Allergy Clin Immunol. 2015;136:703-712.e710. https:\/\/doi.org\/10.1016\/j.jaci.2015.02.022.","journal-title":"J Allergy Clin Immunol"},{"key":"1621_CR45","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1084\/jem.20190147","volume":"216","author":"MT Lam","year":"2019","unstructured":"Lam MT, et al. A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. J Exp Med. 2019;216:2778\u201399. https:\/\/doi.org\/10.1084\/jem.20190147.","journal-title":"J Exp Med"},{"key":"1621_CR46","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jaci.2021.03.045","volume":"148","author":"S Vavassori","year":"2021","unstructured":"Vavassori S, et al. Multisystem inflammation and susceptibility to viral infections in human ZNFX1 deficiency. J Allergy Clin Immunol. 2021;148:381\u201393. https:\/\/doi.org\/10.1016\/j.jaci.2021.03.045.","journal-title":"J Allergy Clin Immunol"},{"key":"1621_CR47","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/(SICI)1096-8628(19991203)87:4<329::AID-AJMG9>3.0.CO;2-M","volume":"87","author":"M Aric\u00f2","year":"1999","unstructured":"Aric\u00f2 M, et al. Hemophagocytic lymphohistiocytosis in a patient with deletion of 22q11.2. Am J Med Genet. 1999;87:329\u201330.","journal-title":"Am J Med Genet"},{"key":"1621_CR48","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/s0022-3476(99)70423-3","volume":"134","author":"M Duval","year":"1999","unstructured":"Duval M, et al. Intermittent hemophagocytic lymphohistiocytosis is a regular feature of lysinuric protein intolerance. J Pediatr. 1999;134:236\u20139. https:\/\/doi.org\/10.1016\/s0022-3476(99)70423-3.","journal-title":"J Pediatr"},{"key":"1621_CR49","first-page":"366","volume":"4","author":"E Grunebaum","year":"2002","unstructured":"Grunebaum E, Roifman CM. Gene abnormalities in patients with hemophagocytic lymphohistiocytosis. Isr Med Assoc J. 2002;4:366\u20139.","journal-title":"Isr Med Assoc J"},{"key":"1621_CR50","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.22409","volume":"56","author":"D Rigante","year":"2007","unstructured":"Rigante D, et al. First report of macrophage activation syndrome in hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum. 2007;56:658\u201361. https:\/\/doi.org\/10.1002\/art.22409.","journal-title":"Arthritis Rheum"},{"key":"1621_CR51","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/bjh.17058","volume":"191","author":"AC Chidambaram","year":"2020","unstructured":"Chidambaram AC, Maulik K, Ramamoorthy JG, Parameswaran N. A novel mutation of adenosine deaminase causing SCID presenting as hemophagocytic lymphohistiocytosis with acute kidney injury. Br J Haematol. 2020;191:509\u201312. https:\/\/doi.org\/10.1111\/bjh.17058.","journal-title":"Br J Haematol"},{"key":"1621_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar3843","volume":"14","author":"SF Bode","year":"2012","unstructured":"Bode SF, et al. Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis. Arthritis Res Ther. 2012;14:1\u201312.","journal-title":"Arthritis Res Ther"},{"key":"1621_CR53","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/(sici)1096-911x(199705)28:5<342::aid-mpo3>3.0.co;2-h","volume":"28","author":"JI Henter","year":"1997","unstructured":"Henter JI, et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis HLH study Group of the Histiocyte Society. Med Pediatr Oncol. 1997;28:342\u20137. https:\/\/doi.org\/10.1002\/(sici)1096-911x(199705)28:5%3c342::aid-mpo3%3e3.0.co;2-h.","journal-title":"Med Pediatr Oncol"},{"key":"1621_CR54","first-page":"4577","volume":"118","author":"H Trottestam","year":"2011","unstructured":"Trottestam H, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood J Am Soc Hematol. 2011;118:4577\u201384.","journal-title":"Blood J Am Soc Hematol"},{"key":"1621_CR55","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4049\/jimmunol.1302282","volume":"192","author":"TS Johnson","year":"2014","unstructured":"Johnson TS, et al. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. J Immunol. 2014;192:84\u201391.","journal-title":"J Immunol"},{"key":"1621_CR56","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40164-022-00362-2","volume":"12","author":"TCE Zondag","year":"2023","unstructured":"Zondag TCE, Lika A, van Laar JAM. The role of etoposide in the treatment of adult patients with hemophagocytic lymphohistiocytosis. Exp Hematol Oncol. 2023;12:2. https:\/\/doi.org\/10.1186\/s40164-022-00362-2.","journal-title":"Exp Hematol Oncol"},{"key":"1621_CR57","first-page":"2728","volume":"130","author":"E Bergsten","year":"2017","unstructured":"Bergsten E, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood J Am Soc Hematol. 2017;130:2728\u201338.","journal-title":"Blood J Am Soc Hematol"},{"key":"1621_CR58","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1651-2227.2011.02501.x","volume":"101","author":"H Trottestam","year":"2012","unstructured":"Trottestam H, et al. Risk factors for early death in children with haemophagocytic lymphohistiocytosis. Acta Paediatr. 2012;101:313\u20138.","journal-title":"Acta Paediatr"},{"key":"1621_CR59","doi-asserted-by":"publisher","first-page":"7258","DOI":"10.1182\/bloodadvances.2023010546","volume":"7","author":"B Verkamp","year":"2023","unstructured":"Verkamp B, et al. Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis. Blood Adv. 2023;7:7258\u201369.","journal-title":"Blood Adv"},{"key":"1621_CR60","first-page":"2367","volume":"100","author":"J-I Henter","year":"2002","unstructured":"Henter J-I, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood J Am Soc Hematol. 2002;100:2367\u201373.","journal-title":"Blood J Am Soc Hematol"},{"key":"1621_CR61","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s00277-022-04946-0","volume":"101","author":"L Chen","year":"2022","unstructured":"Chen L, Wang J, Wang Z. L-DEP regimen is effective as an initial therapy for adult EBV-HLH. Ann Hematol. 2022;101:2461\u201370. https:\/\/doi.org\/10.1007\/s00277-022-04946-0.","journal-title":"Ann Hematol"},{"key":"1621_CR62","first-page":"2186","volume":"126","author":"Y Wang","year":"2015","unstructured":"Wang Y, et al. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood J Am Soc Hematol. 2015;126:2186\u201392.","journal-title":"Blood J Am Soc Hematol"},{"key":"1621_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-016-0317-7","volume":"9","author":"J Wang","year":"2016","unstructured":"Wang J, et al. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Hematol Oncol. 2016;9:1\u201310.","journal-title":"J Hematol Oncol"},{"key":"1621_CR64","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s41409-022-01668-9","volume":"57","author":"A Masood","year":"2022","unstructured":"Masood A, et al. Efficacy and safety of allogeneic hematopoietic stem cell transplant in adults with hemophagocytic lymphohistiocytosis: a systematic review of literature. Bone Marrow Transplant. 2022;57:866\u201373. https:\/\/doi.org\/10.1038\/s41409-022-01668-9.","journal-title":"Bone Marrow Transplant"},{"key":"1621_CR65","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1080\/10245332.2018.1491093","volume":"23","author":"W Lai","year":"2018","unstructured":"Lai W, et al. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents-a life-threatening disease: analysis of 133 cases from a single center. Hematology. 2018;23:810\u20136. https:\/\/doi.org\/10.1080\/10245332.2018.1491093.","journal-title":"Hematology"},{"key":"1621_CR66","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1182\/bloodadvances.2022007012","volume":"7","author":"M Gooptu","year":"2023","unstructured":"Gooptu M, et al. Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis. Blood Adv. 2023;7:2309\u201316. https:\/\/doi.org\/10.1182\/bloodadvances.2022007012.","journal-title":"Blood Adv"},{"key":"1621_CR67","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jaci.2021.07.031","volume":"149","author":"RA Marsh","year":"2022","unstructured":"Marsh RA, et al. Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders. J Allergy Clin Immunol. 2022;149:1097-1104.e1092. https:\/\/doi.org\/10.1016\/j.jaci.2021.07.031.","journal-title":"J Allergy Clin Immunol"},{"key":"1621_CR68","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41409-019-0637-7","volume":"55","author":"RD Sandler","year":"2020","unstructured":"Sandler RD, et al. Haemophagocytic lymphohistiocytosis (HLH) following allogeneic haematopoietic stem cell transplantation (HSCT)-time to reappraise with modern diagnostic and treatment strategies? Bone Marrow Transplant. 2020;55:307\u201316. https:\/\/doi.org\/10.1038\/s41409-019-0637-7.","journal-title":"Bone Marrow Transplant"},{"key":"1621_CR69","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/pbc.23384","volume":"59","author":"T Asano","year":"2012","unstructured":"Asano T, et al. Hemophagocytic lymphohistiocytosis after hematopoietic stem cell transplantation in children: a nationwide survey in Japan. Pediatr Blood Cancer. 2012;59:110\u20134.","journal-title":"Pediatr Blood Cancer"},{"key":"1621_CR70","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41409-019-0711-1","volume":"55","author":"RM Alblooshi","year":"2020","unstructured":"Alblooshi RM, et al. My jamais vu in post allogeneic hematopoietic cell transplant: a review on secondary hemophagocytosis in adults. Bone Marrow Transplant. 2020;55:867\u201372.","journal-title":"Bone Marrow Transplant"},{"key":"1621_CR71","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12185-009-0261-1","volume":"89","author":"A Abdelkefi","year":"2009","unstructured":"Abdelkefi A, et al. Hemophagocytic syndrome after hematopoietic stem cell transplantation: a prospective observational study. Int J Hematol. 2009;89:368\u201373.","journal-title":"Int J Hematol"},{"key":"1621_CR72","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fimmu.2020.00524","volume":"11","author":"RD Sandler","year":"2020","unstructured":"Sandler RD, et al. Diagnosis and Management of Secondary HLH\/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). Front Immunol. 2020;11:524. https:\/\/doi.org\/10.3389\/fimmu.2020.00524.","journal-title":"Front Immunol"},{"key":"1621_CR73","doi-asserted-by":"publisher","first-page":"eadi0042","DOI":"10.1126\/sciimmunol.adi0042","volume":"9","author":"X Li","year":"2024","unstructured":"Li X, et al. Precise CRISPR-Cas9 gene repair in autologous memory T cells to treat familial hemophagocytic lymphohistiocytosis. Sci Immunol. 2024;9:eadi0042. https:\/\/doi.org\/10.1126\/sciimmunol.adi0042.","journal-title":"Sci Immunol"},{"key":"1621_CR74","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jaci.2023.08.003","volume":"153","author":"V Dettmer-Monaco","year":"2024","unstructured":"Dettmer-Monaco V, et al. Gene editing of hematopoietic stem cells restores T-cell response in familial hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol. 2024;153:243-255.e214. https:\/\/doi.org\/10.1016\/j.jaci.2023.08.003.","journal-title":"J Allergy Clin Immunol"},{"key":"1621_CR75","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/mt.2014.242","volume":"23","author":"M Carmo","year":"2015","unstructured":"Carmo M, et al. Perforin gene transfer into hematopoietic stem cells improves immune dysregulation in murine models of perforin deficiency. Mol Ther. 2015;23:737\u201345.","journal-title":"Mol Ther"},{"key":"1621_CR76","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.jaci.2017.11.050","volume":"142","author":"S Ghosh","year":"2018","unstructured":"Ghosh S, et al. T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations. J Allergy Clin Immunol. 2018;142:904-913.e903. https:\/\/doi.org\/10.1016\/j.jaci.2017.11.050.","journal-title":"J Allergy Clin Immunol"},{"key":"1621_CR77","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1182\/bloodadvances.2017012088","volume":"1","author":"T Soheili","year":"2017","unstructured":"Soheili T, et al. Gene transfer into hematopoietic stem cells reduces HLH manifestations in a murine model of Munc13-4 deficiency. Blood Adv. 2017;1:2781\u20139.","journal-title":"Blood Adv"},{"key":"1621_CR78","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1089\/hum.2019.329","volume":"31","author":"SE Takushi","year":"2020","unstructured":"Takushi SE, et al. Lentiviral gene therapy for familial hemophagocytic lymphohistiocytosis type 3, caused by UNC13D genetic defects. Hum Gene Ther. 2020;31:626\u201338.","journal-title":"Hum Gene Ther"},{"key":"1621_CR79","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s10875-022-01389-0","volume":"43","author":"J Topal","year":"2023","unstructured":"Topal J, et al. Lentiviral gene transfer corrects immune abnormalities in XIAP deficiency. J Clin Immunol. 2023;43:440\u201351. https:\/\/doi.org\/10.1007\/s10875-022-01389-0.","journal-title":"J Clin Immunol"},{"key":"1621_CR80","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202216085","volume":"14","author":"K Wei\u00dfert","year":"2022","unstructured":"Wei\u00dfert K, et al. Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis (HLH). EMBO Mol Med. 2022;14: e16085. https:\/\/doi.org\/10.15252\/emmm.202216085.","journal-title":"EMBO Mol Med"},{"key":"1621_CR81","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-057848","author":"J Gupta","year":"2023","unstructured":"Gupta J, et al. Primary hemophagocytic lymphohistiocytosis with prolonged primary neurologic presentation. Pediatrics. 2023. https:\/\/doi.org\/10.1542\/peds.2022-057848.","journal-title":"Pediatrics"},{"key":"1621_CR82","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s10875-020-00814-6","volume":"40","author":"A Blincoe","year":"2020","unstructured":"Blincoe A, et al. Neuroinflammatory Disease as an Isolated Manifestation of Hemophagocytic Lymphohistiocytosis. J Clin Immunol. 2020;40:901\u201316. https:\/\/doi.org\/10.1007\/s10875-020-00814-6.","journal-title":"J Clin Immunol"},{"key":"1621_CR83","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/tcrm.S195538","volume":"17","author":"H Yildiz","year":"2021","unstructured":"Yildiz H, Bailly S, Van Den Neste E, Yombi JC. Clinical management of relapsed\/refractory hemophagocytic lymphohistiocytosis in adult patients: a review of current strategies and emerging therapies. Ther Clin Risk Manag. 2021;17:293\u2013304. https:\/\/doi.org\/10.2147\/tcrm.S195538.","journal-title":"Ther Clin Risk Manag"},{"key":"1621_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061839","author":"JC Lee","year":"2023","unstructured":"Lee JC, Logan AC. Diagnosis and management of adult malignancy-associated hemophagocytic lymphohistiocytosis. Cancers. 2023. https:\/\/doi.org\/10.3390\/cancers15061839.","journal-title":"Cancers"},{"key":"1621_CR85","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1365-2141.2007.06922.x","volume":"140","author":"A Horne","year":"2008","unstructured":"Horne A, et al. Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis. Br J Haematol. 2008;140:327\u201335.","journal-title":"Br J Haematol"},{"key":"1621_CR86","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1007\/s00277-023-05271-w","volume":"102","author":"A Abdelhay","year":"2023","unstructured":"Abdelhay A, et al. Delay in treatment of adult hemophagocytic lymphohistiocytosis is associated with worse in-hospital outcomes. Ann Hematol. 2023;102:2989\u201396. https:\/\/doi.org\/10.1007\/s00277-023-05271-w.","journal-title":"Ann Hematol"},{"key":"1621_CR87","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","volume":"18","author":"LB Ivashkiv","year":"2018","unstructured":"Ivashkiv LB. IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18:545\u201358. https:\/\/doi.org\/10.1038\/s41577-018-0029-z.","journal-title":"Nat Rev Immunol"},{"key":"1621_CR88","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41584-021-00694-z","volume":"17","author":"F De Benedetti","year":"2021","unstructured":"De Benedetti F, Prencipe G, Bracaglia C, Marasco E, Grom AA. Targeting interferon-\u03b3 in hyperinflammation: opportunities and challenges. Nat Rev Rheumatol. 2021;17:678\u201391. https:\/\/doi.org\/10.1038\/s41584-021-00694-z.","journal-title":"Nat Rev Rheumatol"},{"key":"1621_CR89","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-016-0299-5","volume":"9","author":"Y Hu","year":"2016","unstructured":"Hu Y, et al. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J Hematol Oncol. 2016;9:70. https:\/\/doi.org\/10.1186\/s13045-016-0299-5.","journal-title":"J Hematol Oncol"},{"key":"1621_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113683","volume":"155","author":"H Ding","year":"2022","unstructured":"Ding H, Wang G, Yu Z, Sun H, Wang L. Role of interferon-gamma (IFN-\u03b3) and IFN-\u03b3 receptor 1\/2 (IFN\u03b3R1\/2) in regulation of immunity, infection, and cancer development: IFN-\u03b3-dependent or independent pathway. Biomed Pharmacother. 2022;155: 113683. https:\/\/doi.org\/10.1016\/j.biopha.2022.113683.","journal-title":"Biomed Pharmacother"},{"key":"1621_CR91","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/icb.2012.9","volume":"90","author":"NA de Weerd","year":"2012","unstructured":"de Weerd NA, Nguyen T. The interferons and their receptors\u2013distribution and regulation. Immunol Cell Biol. 2012;90:483\u201391. https:\/\/doi.org\/10.1038\/icb.2012.9.","journal-title":"Immunol Cell Biol"},{"key":"1621_CR92","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1158\/1078-0432.CCR-11-0482","volume":"17","author":"MR Zaidi","year":"2011","unstructured":"Zaidi MR, Merlino G. The two faces of interferon-\u03b3 in cancer. Clin Cancer Res. 2011;17:6118\u201324.","journal-title":"Clin Cancer Res"},{"key":"1621_CR93","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nri1604","volume":"5","author":"LC Platanias","year":"2005","unstructured":"Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5:375\u201386. https:\/\/doi.org\/10.1038\/nri1604.","journal-title":"Nat Rev Immunol"},{"key":"1621_CR94","doi-asserted-by":"publisher","first-page":"1190333","DOI":"10.3389\/fimmu.2023.1190333","volume":"14","author":"J Han","year":"2023","unstructured":"Han J, Wu M, Liu Z. Dysregulation in IFN-\u03b3 signaling and response: the barricade to tumor immunotherapy. Front Immunol. 2023;14:1190333. https:\/\/doi.org\/10.3389\/fimmu.2023.1190333.","journal-title":"Front Immunol"},{"key":"1621_CR95","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.immuni.2009.09.002","volume":"31","author":"X Hu","year":"2009","unstructured":"Hu X, Ivashkiv LB. Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity. 2009;31:539\u201350. https:\/\/doi.org\/10.1016\/j.immuni.2009.09.002.","journal-title":"Immunity"},{"key":"1621_CR96","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","volume":"104","author":"MB Jordan","year":"2004","unstructured":"Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood. 2004;104:735\u201343. https:\/\/doi.org\/10.1182\/blood-2003-10-3413.","journal-title":"Blood"},{"key":"1621_CR97","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1002\/jcp.26429","volume":"233","author":"A Shapouri-Moghaddam","year":"2018","unstructured":"Shapouri-Moghaddam A, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233:6425\u201340. https:\/\/doi.org\/10.1002\/jcp.26429.","journal-title":"J Cell Physiol"},{"key":"1621_CR98","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen S, et al. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8:207. https:\/\/doi.org\/10.1038\/s41392-023-01452-1.","journal-title":"Signal Transduct Target Ther"},{"key":"1621_CR99","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jpeds.2011.11.046","volume":"160","author":"XJ Xu","year":"2012","unstructured":"Xu XJ, et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr. 2012;160:984-990.e981. https:\/\/doi.org\/10.1016\/j.jpeds.2011.11.046.","journal-title":"J Pediatr"},{"key":"1621_CR100","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1365-2141.1994.tb04905.x","volume":"87","author":"K Akashi","year":"1994","unstructured":"Akashi K, et al. Involvement of interferon-gamma and macrophage colony-stimulating factor in pathogenesis of haemophagocytic lymphohistiocytosis in adults. Br J Haematol. 1994;87:243\u201350. https:\/\/doi.org\/10.1111\/j.1365-2141.1994.tb04905.x.","journal-title":"Br J Haematol"},{"key":"1621_CR101","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cyto.2016.05.022","volume":"85","author":"SL Yang","year":"2016","unstructured":"Yang SL, et al. Associations between inflammatory cytokines and organ damage in pediatric patients with hemophagocytic lymphohistiocytosis. Cytokine. 2016;85:14\u20137. https:\/\/doi.org\/10.1016\/j.cyto.2016.05.022.","journal-title":"Cytokine"},{"key":"1621_CR102","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/art.37958","volume":"65","author":"SW Canna","year":"2013","unstructured":"Canna SW, et al. Interferon-\u03b3 mediates anemia but is dispensable for fulminant Toll-like receptor 9\u2013induced macrophage activation syndrome and hemophagocytosis in mice. Arthritis Rheum. 2013;65:1764\u201375.","journal-title":"Arthritis Rheum"},{"key":"1621_CR103","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/emmm.200900009","volume":"1","author":"JP Schmid","year":"2009","unstructured":"Schmid JP, et al. Neutralization of IFN\u03b3 defeats haemophagocytosis in LCMV-infected perforin-and Rab27a-deficient mice. EMBO Mol Med. 2009;1:112\u201324.","journal-title":"EMBO Mol Med"},{"key":"1621_CR104","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.trsl.2016.07.023","volume":"180","author":"V Buatois","year":"2017","unstructured":"Buatois V, et al. Use of a mouse model to identify a blood biomarker for IFN\u03b3 activity in pediatric secondary hemophagocytic lymphohistiocytosis. Transl Res. 2017;180:37-52.e32. https:\/\/doi.org\/10.1016\/j.trsl.2016.07.023.","journal-title":"Transl Res"},{"key":"1621_CR105","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1182\/blood.2019000761","volume":"134","author":"S Albeituni","year":"2019","unstructured":"Albeituni S, et al. Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis. Blood. 2019;134:147\u201359. https:\/\/doi.org\/10.1182\/blood.2019000761.","journal-title":"Blood"},{"key":"1621_CR106","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-018-1046-8","volume":"79","author":"Z Al-Salama","year":"2019","unstructured":"Al-Salama Z. T. Emapalumab: first global approval. Drugs. 2019;79:99\u2013103. https:\/\/doi.org\/10.1007\/s40265-018-1046-8.","journal-title":"Drugs"},{"key":"1621_CR107","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-018-1046-8","volume":"79","author":"Z Al-Salama","year":"2019","unstructured":"Al-Salama Z. T. Emapalumab: first global approval. Drugs. 2019;79:99\u2013103.","journal-title":"Drugs"},{"key":"1621_CR108","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","volume":"382","author":"F Locatelli","year":"2020","unstructured":"Locatelli F, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020;382:1811\u201322.","journal-title":"N Engl J Med"},{"key":"1621_CR109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050026","volume":"5","author":"M Rottman","year":"2008","unstructured":"Rottman M, et al. IFN-gamma mediates the rejection of haematopoietic stem cells in IFN-gammaR1-deficient hosts. PLoS Med. 2008;5: e26. https:\/\/doi.org\/10.1371\/journal.pmed.0050026.","journal-title":"PLoS Med"},{"key":"1621_CR110","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3324\/haematol.2020.255620","volume":"106","author":"F Tucci","year":"2021","unstructured":"Tucci F, et al. Emapalumab treatment in an ADA-SCID patient with refractory hemophagocytic lymphohistiocytosis-related graft failure and disseminated bacillus Calmette-Gu\u00e9rin infection. Haematologica. 2021;106:641.","journal-title":"Haematologica"},{"key":"1621_CR111","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.3324\/haematol.2019.216101","volume":"104","author":"P Merli","year":"2019","unstructured":"Merli P, et al. Role of interferon-\u03b3 in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation. Haematologica. 2019;104:2314.","journal-title":"Haematologica"},{"key":"1621_CR112","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/ard-2022-223739","volume":"82","author":"F De Benedetti","year":"2023","unstructured":"De Benedetti F, et al. Efficacy and safety of emapalumab in macrophage activation syndrome. Ann Rheum Dis. 2023;82:857\u201365. https:\/\/doi.org\/10.1136\/ard-2022-223739.","journal-title":"Ann Rheum Dis"},{"key":"1621_CR113","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/imr.13298","volume":"322","author":"MB Jordan","year":"2024","unstructured":"Jordan MB. Hemophagocytic lymphohistiocytosis: A disorder of T cell activation, immune regulation, and distinctive immunopathology. Immunol Rev. 2024;322:339\u201350. https:\/\/doi.org\/10.1111\/imr.13298.","journal-title":"Immunol Rev"},{"key":"1621_CR114","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3324\/haematol.2020.255620","volume":"106","author":"F Tucci","year":"2021","unstructured":"Tucci F, et al. Emapalumab treatment in an ADA-SCID patient with refractory hemophagocytic lymphohistiocytosis-related graft failure and disseminated bacillus Calmette-Gu\u00e9rin infection. Haematologica. 2021;106:641\u20136. https:\/\/doi.org\/10.3324\/haematol.2020.255620.","journal-title":"Haematologica"},{"key":"1621_CR115","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/bloodadvances.2018025858","volume":"3","author":"DT Lounder","year":"2019","unstructured":"Lounder DT, Bin Q, de Min C, Jordan MB. Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections. Blood Adv. 2019;3:47\u201350.","journal-title":"Blood Adv"},{"key":"1621_CR116","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/17512433.2021.1901576","volume":"14","author":"C Garonzi","year":"2021","unstructured":"Garonzi C, Chinello M, Cesaro S. Emapalumab for adult and pediatric patients with hemophagocytic lymphohistiocytosis. Expert Rev Clin Pharmacol. 2021;14:527\u201334. https:\/\/doi.org\/10.1080\/17512433.2021.1901576.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1621_CR117","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1182\/blood.2019002289","volume":"134","author":"M Vallurupalli","year":"2019","unstructured":"Vallurupalli M, Berliner N. Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis. Blood. 2019;134:1783\u20136. https:\/\/doi.org\/10.1182\/blood.2019002289.","journal-title":"Blood"},{"key":"1621_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.608492","volume":"11","author":"P Merli","year":"2020","unstructured":"Merli P, Algeri M, Gaspari S, Locatelli F. Novel therapeutic approaches to familial HLH (emapalumab in FHL). Front Immunol. 2020;11: 608492. https:\/\/doi.org\/10.3389\/fimmu.2020.608492.","journal-title":"Front Immunol"},{"key":"1621_CR119","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/art.41076","volume":"72","author":"TN Burn","year":"2020","unstructured":"Burn TN, et al. Genetic deficiency of interferon-\u03b3 Reveals interferon-\u03b3-independent manifestations of murine hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2020;72:335\u201347. https:\/\/doi.org\/10.1002\/art.41076.","journal-title":"Arthritis Rheumatol"},{"key":"1621_CR120","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28886","volume":"68","author":"S Ehl","year":"2021","unstructured":"Ehl S, et al. Is neutralization of IFN-\u03b3 sufficient to control inflammation in HLH? Pediatr Blood Cancer. 2021;68: e28886. https:\/\/doi.org\/10.1002\/pbc.28886.","journal-title":"Pediatr Blood Cancer"},{"key":"1621_CR121","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6:402. https:\/\/doi.org\/10.1038\/s41392-021-00791-1.","journal-title":"Signal Transduct Target Ther"},{"key":"1621_CR122","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13045-021-01214-y","volume":"14","author":"N Awasthi","year":"2021","unstructured":"Awasthi N, Liongue C, Ward AC. STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer. J Hematol Oncol. 2021;14:198. https:\/\/doi.org\/10.1186\/s13045-021-01214-y.","journal-title":"J Hematol Oncol"},{"key":"1621_CR123","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue C, et al. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther. 2023;8:204. https:\/\/doi.org\/10.1038\/s41392-023-01468-7.","journal-title":"Signal Transduct Target Ther"},{"key":"1621_CR124","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ni.3691","volume":"18","author":"AV Villarino","year":"2017","unstructured":"Villarino AV, Kanno Y, O\u2019Shea JJ. Mechanisms and consequences of Jak\u2013STAT signaling in the immune system. Nat Immunol. 2017;18:374\u201384. https:\/\/doi.org\/10.1038\/ni.3691.","journal-title":"Nat Immunol"},{"key":"1621_CR125","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0092-8674(93)90415-M","volume":"74","author":"LS Argetsinger","year":"1993","unstructured":"Argetsinger LS, et al. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell. 1993;74:237\u201344.","journal-title":"Cell"},{"key":"1621_CR126","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","volume":"27","author":"R Morris","year":"2018","unstructured":"Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK\/STAT pathway. Protein Sci. 2018;27:1984\u20132009. https:\/\/doi.org\/10.1002\/pro.3519.","journal-title":"Protein Sci"},{"key":"1621_CR127","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4161\/jkst.19418","volume":"1","author":"Y Wang","year":"2012","unstructured":"Wang Y, Levy DE. Comparative evolutionary genomics of the STAT family of transcription factors. Jak-Stat. 2012;1:23\u201336.","journal-title":"Jak-Stat"},{"key":"1621_CR128","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/ncponc0195","volume":"2","author":"EB Haura","year":"2005","unstructured":"Haura EB, Turkson J, Jove R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol. 2005;2:315\u201324.","journal-title":"Nat Clin Pract Oncol"},{"key":"1621_CR129","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O'Shea","year":"2015","unstructured":"O\u2019Shea JJ, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311\u201328.","journal-title":"Annu Rev Med"},{"key":"1621_CR130","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/key432","volume":"58","author":"M Gadina","year":"2019","unstructured":"Gadina M, et al. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology. 2019;58:i4\u201316.","journal-title":"Rheumatology"},{"key":"1621_CR131","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021046","author":"C Keenan","year":"2024","unstructured":"Keenan C, et al. Differential effects of JAK1 vs. JAK2 inhibition in mouse models of hemophagocytic lymphohistiocytosis. Blood. 2024. https:\/\/doi.org\/10.1182\/blood.2023021046.","journal-title":"Blood"},{"key":"1621_CR132","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1634\/theoncologist.2019-0627","volume":"25","author":"D Przepiorka","year":"2020","unstructured":"Przepiorka D, et al. FDA approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease. Oncologist. 2020;25:e328\u201334. https:\/\/doi.org\/10.1634\/theoncologist.2019-0627.","journal-title":"Oncologist"},{"key":"1621_CR133","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","volume":"18","author":"J Mascarenhas","year":"2012","unstructured":"Mascarenhas J, Hoffman R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res. 2012;18:3008\u201314.","journal-title":"Clin Cancer Res"},{"key":"1621_CR134","first-page":"1666","volume":"127","author":"R Das","year":"2016","unstructured":"Das R, et al. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood J Am Soc Hematol. 2016;127:1666\u201375.","journal-title":"Blood J Am Soc Hematol"},{"key":"1621_CR135","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1182\/blood-2016-02-700013","volume":"128","author":"S Maschalidi","year":"2016","unstructured":"Maschalidi S, Sepulveda FE, Garrigue A, Fischer A, de Saint Basile G. Therapeutic effect of JAK1\/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood. 2016;128:60\u201371. https:\/\/doi.org\/10.1182\/blood-2016-02-700013.","journal-title":"Blood"},{"key":"1621_CR136","first-page":"657","volume":"136","author":"LK Meyer","year":"2020","unstructured":"Meyer LK, et al. JAK\/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation. Blood J Am Soc Hematol. 2020;136:657\u201368.","journal-title":"Blood J Am Soc Hematol"},{"key":"1621_CR137","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jaci.2022.07.026","volume":"151","author":"JA Joly","year":"2023","unstructured":"Joly JA, et al. Combined IFN-\u03b3 and JAK inhibition to treat hemophagocytic lymphohistiocytosis in mice. J Allergy Clin Immunol. 2023;151:247-259.e247. https:\/\/doi.org\/10.1016\/j.jaci.2022.07.026.","journal-title":"J Allergy Clin Immunol"},{"key":"1621_CR138","doi-asserted-by":"publisher","first-page":"1137037","DOI":"10.3389\/fimmu.2023.1137037","volume":"14","author":"S Albeituni","year":"2023","unstructured":"Albeituni S, et al. Cellular and transcriptional impacts of Janus kinase and\/or IFN-gamma inhibition in a mouse model of primary hemophagocytic lymphohistiocytosis. Front Immunol. 2023;14:1137037. https:\/\/doi.org\/10.3389\/fimmu.2023.1137037.","journal-title":"Front Immunol"},{"key":"1621_CR139","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1182\/blood.2020007930","volume":"138","author":"V Chaturvedi","year":"2021","unstructured":"Chaturvedi V, Lakes N, Tran M, Castillo N, Jordan MB. JAK inhibition for murine HLH requires complete blockade of IFN-\u03b3 signaling and is limited by toxicity of JAK2 inhibition. Blood. 2021;138:1034\u20139. https:\/\/doi.org\/10.1182\/blood.2020007930.","journal-title":"Blood"},{"key":"1621_CR140","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.222471","volume":"105","author":"J Wang","year":"2020","unstructured":"Wang J, et al. Ruxolitinib for refractory\/relapsed hemophagocytic lymphohistiocytosis. Haematologica. 2020;105: e210.","journal-title":"Haematologica"},{"key":"1621_CR141","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s12185-020-02936-4","volume":"112","author":"A Wei","year":"2020","unstructured":"Wei A, et al. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children. Int J Hematol. 2020;112:568\u201376.","journal-title":"Int J Hematol"},{"key":"1621_CR142","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjh.17331","volume":"193","author":"J Wang","year":"2021","unstructured":"Wang J, et al. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory\/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial. Br J Haematol. 2021;193:761\u20138. https:\/\/doi.org\/10.1111\/bjh.17331.","journal-title":"Br J Haematol"},{"key":"1621_CR143","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28071","volume":"67","author":"KM Ramanan","year":"2020","unstructured":"Ramanan KM, et al. Successful remission induction in refractory familial hemophagocytic lymphohistiocytosis with ruxolitinib as a bridge to hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2020;67: e28071.","journal-title":"Pediatr Blood Cancer"},{"key":"1621_CR144","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41409-019-0577-2","volume":"55","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, et al. Salvage therapy with dose-escalating ruxolitinib as a bridge to allogeneic stem cell transplantation for refractory hemophagocytic lymphohistiocytosis. Bone Marrow Transplant. 2020;55:824\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"1621_CR145","doi-asserted-by":"publisher","first-page":"E47","DOI":"10.1002\/ajh.24971","volume":"93","author":"J Slostad","year":"2018","unstructured":"Slostad J, et al. Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: a single patient experience. Am J Hematol. 2018;93:E47\u20139.","journal-title":"Am J Hematol"},{"key":"1621_CR146","doi-asserted-by":"publisher","first-page":"E123","DOI":"10.1002\/ajh.25063","volume":"93","author":"I Zandvakili","year":"2018","unstructured":"Zandvakili I, Conboy CB, Ayed AO, Cathcart-Rake EJ, Tefferi A. Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: a second experience. Am J Hematol. 2018;93:E123\u20135.","journal-title":"Am J Hematol"},{"key":"1621_CR147","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ijid.2020.07.062","volume":"100","author":"A Fuchs","year":"2020","unstructured":"Fuchs A, et al. Falciparum malaria-induced secondary hemophagocytic lymphohistiocytosis successfully treated with ruxolitinib. Int J Infect Dis. 2020;100:382\u20135. https:\/\/doi.org\/10.1016\/j.ijid.2020.07.062.","journal-title":"Int J Infect Dis"},{"key":"1621_CR148","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4078\/jrd.2023.0027","volume":"31","author":"JI Jung","year":"2024","unstructured":"Jung JI, et al. Successful treatment of hemophagocytic lymphohistiocytosis in a patient with systemic lupus erythematosus with ruxolitinib: a case report. J Rheum Dis. 2024;31:125\u20139. https:\/\/doi.org\/10.4078\/jrd.2023.0027.","journal-title":"J Rheum Dis"},{"key":"1621_CR149","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/ejh.13593","volume":"106","author":"S Hansen","year":"2021","unstructured":"Hansen S, et al. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: a case series. Eur J Haematol. 2021;106:654\u201361. https:\/\/doi.org\/10.1111\/ejh.13593.","journal-title":"Eur J Haematol"},{"key":"1621_CR150","doi-asserted-by":"publisher","first-page":"1012643","DOI":"10.3389\/fimmu.2022.1012643","volume":"13","author":"X Liu","year":"2022","unstructured":"Liu X, et al. Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS. Front Immunol. 2022;13:1012643. https:\/\/doi.org\/10.3389\/fimmu.2022.1012643.","journal-title":"Front Immunol"},{"key":"1621_CR151","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29026","volume":"68","author":"MP Triebwasser","year":"2021","unstructured":"Triebwasser MP, et al. Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective. Pediatr Blood Cancer. 2021;68: e29026. https:\/\/doi.org\/10.1002\/pbc.29026.","journal-title":"Pediatr Blood Cancer"},{"key":"1621_CR152","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/1744666x.2022.2014323","volume":"18","author":"MA Adas","year":"2022","unstructured":"Adas MA, et al. The infection risks of JAK inhibition. Expert Rev Clin Immunol. 2022;18:253\u201361. https:\/\/doi.org\/10.1080\/1744666x.2022.2014323.","journal-title":"Expert Rev Clin Immunol"},{"key":"1621_CR153","doi-asserted-by":"publisher","first-page":"Cd013881","DOI":"10.1002\/14651858.CD013881.pub2","volume":"6","author":"L Ghosn","year":"2023","unstructured":"Ghosn L, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2023;6:Cd013881. https:\/\/doi.org\/10.1002\/14651858.CD013881.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1621_CR154","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00856-y","author":"S Rose-John","year":"2023","unstructured":"Rose-John S, Jenkins BJ, Garbers C, Moll JM, Scheller J. Targeting IL-6 trans-signalling: past, present and future prospects. Nat Rev Immunol. 2023. https:\/\/doi.org\/10.1038\/s41577-023-00856-y.","journal-title":"Nat Rev Immunol"},{"key":"1621_CR155","doi-asserted-by":"publisher","first-page":"e13146","DOI":"10.1097\/md.0000000000013146","volume":"97","author":"X Qiu","year":"2018","unstructured":"Qiu X, et al. Interleukin-6 for early diagnosis of neonatal sepsis with premature rupture of the membranes: a meta-analysis. Medicine. 2018;97:e13146. https:\/\/doi.org\/10.1097\/md.0000000000013146.","journal-title":"Medicine"},{"key":"1621_CR156","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jaci.2020.07.001","volume":"146","author":"A Copaescu","year":"2020","unstructured":"Copaescu A, Smibert O, Gibson A, Phillips EJ, Trubiano JA. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. J Allergy Clin Immunol. 2020;146:518-534.e511. https:\/\/doi.org\/10.1016\/j.jaci.2020.07.001.","journal-title":"J Allergy Clin Immunol"},{"key":"1621_CR157","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24505","volume":"36","author":"G Zeng","year":"2022","unstructured":"Zeng G, et al. Combination of C-reactive protein, procalcitonin, IL-6, IL-8, and IL-10 for early diagnosis of hyperinflammatory state and organ dysfunction in pediatric sepsis. J Clin Lab Anal. 2022;36: e24505. https:\/\/doi.org\/10.1002\/jcla.24505.","journal-title":"J Clin Lab Anal"},{"key":"1621_CR158","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/bjd.12145","volume":"168","author":"JP McFadden","year":"2013","unstructured":"McFadden JP, Puangpet P, Basketter DA, Dearman RJ, Kimber I. Why does allergic contact dermatitis exist? Br J Dermatol. 2013;168:692\u20139. https:\/\/doi.org\/10.1111\/bjd.12145.","journal-title":"Br J Dermatol"},{"key":"1621_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2022.577951","volume":"371","author":"MF Serna-Rodr\u00edguez","year":"2022","unstructured":"Serna-Rodr\u00edguez MF, Bernal-Vega S, de la Barquera JAO, Camacho-Morales A, P\u00e9rez-Maya AA. The role of damage associated molecular pattern molecules (DAMPs) and permeability of the blood-brain barrier in depression and neuroinflammation. J Neuroimmunol. 2022;371: 577951. https:\/\/doi.org\/10.1016\/j.jneuroim.2022.577951.","journal-title":"J Neuroimmunol"},{"key":"1621_CR160","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.thromres.2022.09.025","volume":"220","author":"S Subramaniam","year":"2022","unstructured":"Subramaniam S, Kothari H, Bosmann M. Tissue factor in COVID-19-associated coagulopathy. Thromb Res. 2022;220:35\u201347. https:\/\/doi.org\/10.1016\/j.thromres.2022.09.025.","journal-title":"Thromb Res"},{"key":"1621_CR161","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1006\/cyto.1997.0262","volume":"10","author":"F Rougier","year":"1998","unstructured":"Rougier F, Cornu E, Praloran V, Denizot Y. IL-6 and IL-8 production by human bone marrow stromal cells. Cytokine. 1998;10:93\u20137. https:\/\/doi.org\/10.1006\/cyto.1997.0262.","journal-title":"Cytokine"},{"key":"1621_CR162","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1681\/asn.2006010050","volume":"18","author":"A Sheryanna","year":"2007","unstructured":"Sheryanna A, et al. Inhibition of p38 mitogen-activated protein kinase is effective in the treatment of experimental crescentic glomerulonephritis and suppresses monocyte chemoattractant protein-1 but not IL-1beta or IL-6. J Am Soc Nephrol. 2007;18:1167\u201379. https:\/\/doi.org\/10.1681\/asn.2006010050.","journal-title":"J Am Soc Nephrol"},{"key":"1621_CR163","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1177\/154405910808700614","volume":"87","author":"P Palmqvist","year":"2008","unstructured":"Palmqvist P, Lundberg P, Lundgren I, H\u00e4nstr\u00f6m L, Lerner UH. IL-1beta and TNF-alpha regulate IL-6-type cytokines in gingival fibroblasts. J Dent Res. 2008;87:558\u201363. https:\/\/doi.org\/10.1177\/154405910808700614.","journal-title":"J Dent Res"},{"key":"1621_CR164","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.mce.2016.05.023","volume":"433","author":"S Virakul","year":"2016","unstructured":"Virakul S, et al. Basic FGF and PDGF-BB synergistically stimulate hyaluronan and IL-6 production by orbital fibroblasts. Mol Cell Endocrinol. 2016;433:94\u2013104. https:\/\/doi.org\/10.1016\/j.mce.2016.05.023.","journal-title":"Mol Cell Endocrinol"},{"key":"1621_CR165","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1007\/s10753-017-0634-1","volume":"40","author":"S Hirano","year":"2017","unstructured":"Hirano S, Zhou Q, Furuyama A, Kanno S. Differential regulation of IL-1\u03b2 and IL-6 release in murine macrophages. Inflammation. 2017;40:1933\u201343. https:\/\/doi.org\/10.1007\/s10753-017-0634-1.","journal-title":"Inflammation"},{"key":"1621_CR166","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.709618","volume":"9","author":"SS Al-Asmari","year":"2021","unstructured":"Al-Asmari SS, et al. Pharmacological targeting of STING-dependent IL-6 production in cancer cells. Front Cell Dev Biol. 2021;9: 709618. https:\/\/doi.org\/10.3389\/fcell.2021.709618.","journal-title":"Front Cell Dev Biol"},{"key":"1621_CR167","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","volume":"141","author":"X Yao","year":"2014","unstructured":"Yao X, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141:125\u201339. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.09.004.","journal-title":"Pharmacol Ther"},{"key":"1621_CR168","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2217\/imt-2016-0020","volume":"8","author":"T Tanaka","year":"2016","unstructured":"Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016;8:959\u201370. https:\/\/doi.org\/10.2217\/imt-2016-0020.","journal-title":"Immunotherapy"},{"key":"1621_CR169","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/1744666x.2017.1295850","volume":"13","author":"M Narazaki","year":"2017","unstructured":"Narazaki M, Tanaka T, Kishimoto T. The role and therapeutic targeting of IL-6 in rheumatoid arthritis. Expert Rev Clin Immunol. 2017;13:535\u201351. https:\/\/doi.org\/10.1080\/1744666x.2017.1295850.","journal-title":"Expert Rev Clin Immunol"},{"key":"1621_CR170","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev-immunol-101220-023458","volume":"40","author":"T Kishimoto","year":"2022","unstructured":"Kishimoto T, Kang S. IL-6 revisited: from rheumatoid arthritis to CAR T cell therapy and COVID-19. Annu Rev Immunol. 2022;40:323\u201348. https:\/\/doi.org\/10.1146\/annurev-immunol-101220-023458.","journal-title":"Annu Rev Immunol"},{"key":"1621_CR171","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-023-01432-6","volume":"16","author":"Y Leyfman","year":"2023","unstructured":"Leyfman Y, et al. Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients. J Hematol Oncol. 2023;16:39. https:\/\/doi.org\/10.1186\/s13045-023-01432-6.","journal-title":"J Hematol Oncol"},{"key":"1621_CR172","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-020-00907-0","volume":"13","author":"Y Meng","year":"2020","unstructured":"Meng Y, et al. Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis. J Hematol Oncol. 2020;13:75. https:\/\/doi.org\/10.1186\/s13045-020-00907-0.","journal-title":"J Hematol Oncol"},{"key":"1621_CR173","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/art.1780340912","volume":"34","author":"F de Benedetti","year":"1991","unstructured":"de Benedetti F, et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991;34:1158\u201363. https:\/\/doi.org\/10.1002\/art.1780340912.","journal-title":"Arthritis Rheum"},{"key":"1621_CR174","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020014","volume":"6","author":"D Lasigli\u00e8","year":"2011","unstructured":"Lasigli\u00e8 D, et al. Role of IL-1 beta in the development of human T(H)17 cells: lesson from NLPR3 mutated patients. PLoS ONE. 2011;6: e20014. https:\/\/doi.org\/10.1371\/journal.pone.0020014.","journal-title":"PLoS ONE"},{"key":"1621_CR175","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","volume":"18","author":"SA Jones","year":"2018","unstructured":"Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;18:773\u201389. https:\/\/doi.org\/10.1038\/s41577-018-0066-7.","journal-title":"Nat Rev Immunol"},{"key":"1621_CR176","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1479-7364-5-1-30","volume":"5","author":"C Brocker","year":"2010","unstructured":"Brocker C, Thompson D, Matsumoto A, Nebert DW, Vasiliou V. Evolutionary divergence and functions of the human interleukin (IL) gene family. Hum Genomics. 2010;5:30\u201355. https:\/\/doi.org\/10.1186\/1479-7364-5-1-30.","journal-title":"Hum Genomics"},{"key":"1621_CR177","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00430-006-0019-9","volume":"195","author":"J Scheller","year":"2006","unstructured":"Scheller J, Rose-John S. Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol. 2006;195:173\u201383. https:\/\/doi.org\/10.1007\/s00430-006-0019-9.","journal-title":"Med Microbiol Immunol"},{"key":"1621_CR178","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrd.2018.45","volume":"17","author":"C Garbers","year":"2018","unstructured":"Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov. 2018;17:395\u2013412. https:\/\/doi.org\/10.1038\/nrd.2018.45.","journal-title":"Nat Rev Drug Discov"},{"key":"1621_CR179","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cytogfr.2017.03.003","volume":"37","author":"E Feigerlov\u00e1","year":"2017","unstructured":"Feigerlov\u00e1 E, Battaglia-Hsu SF. IL-6 signaling in diabetic nephropathy: from pathophysiology to therapeutic perspectives. Cytokine Growth Factor Rev. 2017;37:57\u201365. https:\/\/doi.org\/10.1016\/j.cytogfr.2017.03.003.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1621_CR180","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1042\/cs20110340","volume":"122","author":"M Mihara","year":"2012","unstructured":"Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6\/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2012;122:143\u201359. https:\/\/doi.org\/10.1042\/cs20110340.","journal-title":"Clin Sci (Lond)"},{"key":"1621_CR181","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798\u2013809. https:\/\/doi.org\/10.1038\/nrc2734.","journal-title":"Nat Rev Cancer"},{"key":"1621_CR182","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaut.2009.08.003","volume":"34","author":"C Drucker","year":"2010","unstructured":"Drucker C, Gewiese J, Malchow S, Scheller J, Rose-John S. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration. J Autoimmun. 2010;34:29\u201337. https:\/\/doi.org\/10.1016\/j.jaut.2009.08.003.","journal-title":"J Autoimmun"},{"key":"1621_CR183","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1042\/bst20180136","volume":"46","author":"MY Taher","year":"2018","unstructured":"Taher MY, Davies DM, Maher J. The role of the interleukin (IL)-6\/IL-6 receptor axis in cancer. Biochem Soc Trans. 2018;46:1449\u201362. https:\/\/doi.org\/10.1042\/bst20180136.","journal-title":"Biochem Soc Trans"},{"key":"1621_CR184","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12964-019-0356-0","volume":"17","author":"H Reeh","year":"2019","unstructured":"Reeh H, et al. Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor \u03b1 to gp130 expression: fusing experimental insights and dynamic modelling. Cell Commun Signal. 2019;17:46. https:\/\/doi.org\/10.1186\/s12964-019-0356-0.","journal-title":"Cell Commun Signal"},{"key":"1621_CR185","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1161\/01.cir.0000057545.82749.ff","volume":"107","author":"EK Podewski","year":"2003","unstructured":"Podewski EK, et al. Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. Circulation. 2003;107:798\u2013802. https:\/\/doi.org\/10.1161\/01.cir.0000057545.82749.ff.","journal-title":"Circulation"},{"key":"1621_CR186","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jhep.2005.12.019","volume":"45","author":"K Tron","year":"2006","unstructured":"Tron K, et al. Regulation of rat heme oxygenase-1 expression by interleukin-6 via the Jak\/STAT pathway in hepatocytes. J Hepatol. 2006;45:72\u201380. https:\/\/doi.org\/10.1016\/j.jhep.2005.12.019.","journal-title":"J Hepatol"},{"key":"1621_CR187","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cytogfr.2011.02.003","volume":"22","author":"MF Neurath","year":"2011","unstructured":"Neurath MF, Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev. 2011;22:83\u20139. https:\/\/doi.org\/10.1016\/j.cytogfr.2011.02.003.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1621_CR188","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1200\/jco.2010.31.8907","volume":"30","author":"P Sansone","year":"2012","unstructured":"Sansone P, Bromberg J. Targeting the interleukin-6\/Jak\/stat pathway in human malignancies. J Clin Oncol. 2012;30:1005\u201314. https:\/\/doi.org\/10.1200\/jco.2010.31.8907.","journal-title":"J Clin Oncol"},{"key":"1621_CR189","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrrheum.2014.127","volume":"10","author":"LH Calabrese","year":"2014","unstructured":"Calabrese LH, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol. 2014;10:720\u20137. https:\/\/doi.org\/10.1038\/nrrheum.2014.127.","journal-title":"Nat Rev Rheumatol"},{"key":"1621_CR190","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s12276-020-0445-6","volume":"52","author":"NA Sims","year":"2020","unstructured":"Sims NA. The JAK1\/STAT3\/SOCS3 axis in bone development, physiology, and pathology. Exp Mol Med. 2020;52:1185\u201397. https:\/\/doi.org\/10.1038\/s12276-020-0445-6.","journal-title":"Exp Mol Med"},{"key":"1621_CR191","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41575-021-00473-x","volume":"18","author":"MD Giraldez","year":"2021","unstructured":"Giraldez MD, Carneros D, Garbers C, Rose-John S, Bustos M. New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology. Nat Rev Gastroenterol Hepatol. 2021;18:787\u2013803. https:\/\/doi.org\/10.1038\/s41575-021-00473-x.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1621_CR192","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/s2213-2600(21)00103-x","volume":"9","author":"OJ McElvaney","year":"2021","unstructured":"McElvaney OJ, Curley GF, Rose-John S, McElvaney NG. Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir Med. 2021;9:643\u201354. https:\/\/doi.org\/10.1016\/s2213-2600(21)00103-x.","journal-title":"Lancet Respir Med"},{"key":"1621_CR193","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/ni.3632","volume":"18","author":"S Heink","year":"2017","unstructured":"Heink S, et al. Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic T(H)17 cells. Nat Immunol. 2017;18:74\u201385. https:\/\/doi.org\/10.1038\/ni.3632.","journal-title":"Nat Immunol"},{"key":"1621_CR194","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1002\/art.33496","volume":"64","author":"R Strippoli","year":"2012","unstructured":"Strippoli R, et al. Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome. Arthritis Rheum. 2012;64:1680\u20138. https:\/\/doi.org\/10.1002\/art.33496.","journal-title":"Arthritis Rheum"},{"key":"1621_CR195","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1182\/blood-2004-08-2997","volume":"105","author":"AD Billiau","year":"2005","unstructured":"Billiau AD, Roskams T, Van Damme-Lombaerts R, Matthys P, Wouters C. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood. 2005;105:1648\u201351. https:\/\/doi.org\/10.1182\/blood-2004-08-2997.","journal-title":"Blood"},{"key":"1621_CR196","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-med-061813-012806","volume":"66","author":"GS Schulert","year":"2015","unstructured":"Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med. 2015;66:145\u201359. https:\/\/doi.org\/10.1146\/annurev-med-061813-012806.","journal-title":"Annu Rev Med"},{"key":"1621_CR197","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739\u201348. https:\/\/doi.org\/10.1038\/s41591-018-0036-4.","journal-title":"Nat Med"},{"key":"1621_CR198","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1002\/art.39295","volume":"67","author":"L Cifaldi","year":"2015","unstructured":"Cifaldi L, et al. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Arthritis Rheumatol. 2015;67:3037\u201346. https:\/\/doi.org\/10.1002\/art.39295.","journal-title":"Arthritis Rheumatol"},{"key":"1621_CR199","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/art.23199","volume":"58","author":"MM Hazen","year":"2008","unstructured":"Hazen MM, et al. Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2008;58:567\u201370. https:\/\/doi.org\/10.1002\/art.23199.","journal-title":"Arthritis Rheum"},{"key":"1621_CR200","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1002\/art.23734","volume":"58","author":"K Zhang","year":"2008","unstructured":"Zhang K, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. 2008;58:2892\u20136. https:\/\/doi.org\/10.1002\/art.23734.","journal-title":"Arthritis Rheum"},{"key":"1621_CR201","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1002\/art.38793","volume":"66","author":"KM Kaufman","year":"2014","unstructured":"Kaufman KM, et al. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2014;66:3486\u201395. https:\/\/doi.org\/10.1002\/art.38793.","journal-title":"Arthritis Rheumatol"},{"key":"1621_CR202","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385\u201395. https:\/\/doi.org\/10.1056\/NEJMoa1112802.","journal-title":"N Engl J Med"},{"key":"1621_CR203","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.cyto.2012.02.006","volume":"58","author":"M Shimizu","year":"2012","unstructured":"Shimizu M, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine. 2012;58:287\u201394. https:\/\/doi.org\/10.1016\/j.cyto.2012.02.006.","journal-title":"Cytokine"},{"key":"1621_CR204","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/tcrm.S155488","volume":"14","author":"S Zhou","year":"2018","unstructured":"Zhou S, Qiao J, Bai J, Wu Y, Fang H. Biological therapy of traditional therapy-resistant adult-onset Still\u2019s disease: an evidence-based review. Ther Clin Risk Manag. 2018;14:167\u201371. https:\/\/doi.org\/10.2147\/tcrm.S155488.","journal-title":"Ther Clin Risk Manag"},{"key":"1621_CR205","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","volume":"12","author":"AA Grom","year":"2016","unstructured":"Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12:259\u201368. https:\/\/doi.org\/10.1038\/nrrheum.2015.179.","journal-title":"Nat Rev Rheumatol"},{"key":"1621_CR206","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","volume":"146","author":"CW Freyer","year":"2020","unstructured":"Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol. 2020;146:940\u20138. https:\/\/doi.org\/10.1016\/j.jaci.2020.07.025.","journal-title":"J Allergy Clin Immunol"},{"key":"1621_CR207","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001511","author":"MV Maus","year":"2020","unstructured":"Maus MV, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-001511.","journal-title":"J Immunother Cancer"},{"key":"1621_CR208","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1097\/ccm.0000000000005361","volume":"50","author":"MR Hines","year":"2022","unstructured":"Hines MR, et al. Consensus-based guidelines for the recognition, diagnosis, and management of hemophagocytic lymphohistiocytosis in critically Ill children and adults. Crit Care Med. 2022;50:860\u201372. https:\/\/doi.org\/10.1097\/ccm.0000000000005361.","journal-title":"Crit Care Med"},{"key":"1621_CR209","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/s2352-3026(21)00366-5","volume":"9","author":"A Setiadi","year":"2022","unstructured":"Setiadi A, Zoref-Lorenz A, Lee CY, Jordan MB, Chen LYC. Malignancy-associated haemophagocytic lymphohistiocytosis. Lancet Haematol. 2022;9:e217\u201327. https:\/\/doi.org\/10.1016\/s2352-3026(21)00366-5.","journal-title":"Lancet Haematol"},{"key":"1621_CR210","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-019-0819-1","volume":"12","author":"D Liu","year":"2019","unstructured":"Liu D. CAR-T \u201cthe living drugs\u201d, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. J Hematol Oncol. 2019;12:113. https:\/\/doi.org\/10.1186\/s13045-019-0819-1.","journal-title":"J Hematol Oncol"},{"key":"1621_CR211","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28751","volume":"95","author":"MS Qudus","year":"2023","unstructured":"Qudus MS, et al. The roles of critical pro-inflammatory cytokines in the drive of cytokine storm during SARS-CoV-2 infection. J Med Virol. 2023;95: e28751. https:\/\/doi.org\/10.1002\/jmv.28751.","journal-title":"J Med Virol"},{"key":"1621_CR212","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1080\/24725625.2020.1741073","volume":"4","author":"SI Ohmura","year":"2020","unstructured":"Ohmura SI, et al. Successful use of short-term add-on tocilizumab for refractory adult-onset still\u2019s disease with macrophage activation syndrome despite treatment with high-dose glucocorticoids, cyclosporine, and etoposide. Mod Rheumatol Case Rep. 2020;4:202\u20137. https:\/\/doi.org\/10.1080\/24725625.2020.1741073.","journal-title":"Mod Rheumatol Case Rep"},{"key":"1621_CR213","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1016\/j.cgh.2021.10.021","volume":"20","author":"EMJ Beelen","year":"2022","unstructured":"Beelen EMJ, et al. Risk prediction and comparative efficacy of anti-TNF vs thiopurines, for preventing postoperative recurrence in Crohn\u2019s disease: a pooled analysis of 6 trials. Clin Gastroenterol Hepatol. 2022;20:2741-2752.e2746. https:\/\/doi.org\/10.1016\/j.cgh.2021.10.021.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1621_CR214","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1136\/gutjnl-2019-320022","volume":"70","author":"GR D'Haens","year":"2021","unstructured":"D\u2019Haens GR, van Deventer S. 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. Gut. 2021;70:1396\u2013405. https:\/\/doi.org\/10.1136\/gutjnl-2019-320022.","journal-title":"Gut"},{"key":"1621_CR215","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40265-020-01460-3","volume":"81","author":"J Hanzel","year":"2021","unstructured":"Hanzel J, et al. Vedolizumab and extraintestinal manifestations in inflammatory bowel disease. Drugs. 2021;81:333\u201347. https:\/\/doi.org\/10.1007\/s40265-020-01460-3.","journal-title":"Drugs"},{"key":"1621_CR216","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.autrev.2019.03.002","volume":"18","author":"DY Jeong","year":"2019","unstructured":"Jeong DY, et al. Induction and maintenance treatment of inflammatory bowel disease: a comprehensive review. Autoimmun Rev. 2019;18:439\u201354. https:\/\/doi.org\/10.1016\/j.autrev.2019.03.002.","journal-title":"Autoimmun Rev"},{"key":"1621_CR217","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102398","volume":"18","author":"A Rubbert-Roth","year":"2019","unstructured":"Rubbert-Roth A, et al. Failure of anti-TNF treatment in patients with rheumatoid arthritis: the pros and cons of the early use of alternative biological agents. Autoimmun Rev. 2019;18: 102398. https:\/\/doi.org\/10.1016\/j.autrev.2019.102398.","journal-title":"Autoimmun Rev"},{"key":"1621_CR218","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3389\/fimmu.2012.00239","volume":"3","author":"L Chiossone","year":"2012","unstructured":"Chiossone L, et al. Protection from inflammatory organ damage in a murine model of hemophagocytic lymphohistiocytosis using treatment with IL-18 binding protein. Front Immunol. 2012;3:239. https:\/\/doi.org\/10.3389\/fimmu.2012.00239.","journal-title":"Front Immunol"},{"key":"1621_CR219","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.berh.2014.03.002","volume":"28","author":"GS Schulert","year":"2014","unstructured":"Schulert GS, Grom AA. Macrophage activation syndrome and cytokine-directed therapies. Best Pract Res Clin Rheumatol. 2014;28:277\u201392. https:\/\/doi.org\/10.1016\/j.berh.2014.03.002.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1621_CR220","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1002\/eji.200838488","volume":"38","author":"J Pachlopnik Schmid","year":"2008","unstructured":"Pachlopnik Schmid J, et al. A Griscelli syndrome type 2 murine model of hemophagocytic lymphohistiocytosis (HLH). Eur J Immunol. 2008;38:3219\u201325. https:\/\/doi.org\/10.1002\/eji.200838488.","journal-title":"Eur J Immunol"},{"key":"1621_CR221","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.semnephrol.2006.09.013","volume":"27","author":"CA Dinarello","year":"2007","unstructured":"Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol. 2007;27:98\u2013114. https:\/\/doi.org\/10.1016\/j.semnephrol.2006.09.013.","journal-title":"Semin Nephrol"},{"key":"1621_CR222","doi-asserted-by":"publisher","first-page":"5660","DOI":"10.4049\/jimmunol.1100663","volume":"187","author":"AA Kruglov","year":"2011","unstructured":"Kruglov AA, Lampropoulou V, Fillatreau S, Nedospasov SA. Pathogenic and protective functions of TNF in neuroinflammation are defined by its expression in T lymphocytes and myeloid cells. J Immunol. 2011;187:5660\u201370. https:\/\/doi.org\/10.4049\/jimmunol.1100663.","journal-title":"J Immunol"},{"key":"1621_CR223","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/11532610-000000000-00000","volume":"12","author":"S Shenoi","year":"2010","unstructured":"Shenoi S, Wallace CA. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review. Paediatr Drugs. 2010;12:367\u201377. https:\/\/doi.org\/10.2165\/11532610-000000000-00000.","journal-title":"Paediatr Drugs"},{"key":"1621_CR224","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","volume":"184","author":"R Karki","year":"2021","unstructured":"Karki R, et al. Synergism of TNF-\u03b1 and IFN-\u03b3 triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell. 2021;184:149-168.e117. https:\/\/doi.org\/10.1016\/j.cell.2020.11.025.","journal-title":"Cell"},{"key":"1621_CR225","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1073\/pnas.1820704116","volume":"116","author":"A Wang","year":"2019","unstructured":"Wang A, et al. Specific sequences of infectious challenge lead to secondary hemophagocytic lymphohistiocytosis-like disease in mice. Proc Natl Acad Sci U S A. 2019;116:2200\u20139. https:\/\/doi.org\/10.1073\/pnas.1820704116.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1621_CR226","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","volume":"119","author":"BB Aggarwal","year":"2012","unstructured":"Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119:651\u201365. https:\/\/doi.org\/10.1182\/blood-2011-04-325225.","journal-title":"Blood"},{"key":"1621_CR227","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd1287","author":"R Bechara","year":"2021","unstructured":"Bechara R, et al. The m(6)A reader IMP2 directs autoimmune inflammation through an IL-17- and TNF\u03b1-dependent C\/EBP transcription factor axis. Sci Immunol. 2021. https:\/\/doi.org\/10.1126\/sciimmunol.abd1287.","journal-title":"Sci Immunol"},{"key":"1621_CR228","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s13075-018-1725-6","volume":"20","author":"JL Davignon","year":"2018","unstructured":"Davignon JL, et al. Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review. Arthritis Res Ther. 2018;20:229. https:\/\/doi.org\/10.1186\/s13075-018-1725-6.","journal-title":"Arthritis Res Ther"},{"key":"1621_CR229","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","volume":"12","author":"GD Kalliolias","year":"2016","unstructured":"Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12:49\u201362. https:\/\/doi.org\/10.1038\/nrrheum.2015.169.","journal-title":"Nat Rev Rheumatol"},{"key":"1621_CR230","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nri702","volume":"2","author":"JJ O'Shea","year":"2002","unstructured":"O\u2019Shea JJ, Ma A, Lipsky P. Cytokines and autoimmunity. Nat Rev Immunol. 2002;2:37\u201345. https:\/\/doi.org\/10.1038\/nri702.","journal-title":"Nat Rev Immunol"},{"key":"1621_CR231","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","volume":"49","author":"T Horiuchi","year":"2010","unstructured":"Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford). 2010;49:1215\u201328. https:\/\/doi.org\/10.1093\/rheumatology\/keq031.","journal-title":"Rheumatology (Oxford)"},{"key":"1621_CR232","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.3389\/fimmu.2017.01675","volume":"8","author":"Y Qu","year":"2017","unstructured":"Qu Y, Zhao G, Li H. Forward and reverse signaling mediated by transmembrane tumor necrosis factor-alpha and TNF receptor 2: potential roles in an immunosuppressive tumor microenvironment. Front Immunol. 2017;8:1675. https:\/\/doi.org\/10.3389\/fimmu.2017.01675.","journal-title":"Front Immunol"},{"key":"1621_CR233","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.biocel.2010.03.011","volume":"42","author":"KV Ramana","year":"2010","unstructured":"Ramana KV. Tumor necrosis factor-alpha converting enzyme: Implications for ocular inflammatory diseases. Int J Biochem Cell Biol. 2010;42:1076\u20139. https:\/\/doi.org\/10.1016\/j.biocel.2010.03.011.","journal-title":"Int J Biochem Cell Biol"},{"key":"1621_CR234","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/s1359-6101(96)00026-3","volume":"7","author":"D Aderka","year":"1996","unstructured":"Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev. 1996;7:231\u201340. https:\/\/doi.org\/10.1016\/s1359-6101(96)00026-3.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1621_CR235","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.exger.2017.10.012","volume":"100","author":"E Arroyo","year":"2017","unstructured":"Arroyo E, et al. Tumor necrosis factor-alpha and soluble TNF-alpha receptor responses in young vs. middle-aged males following eccentric exercise. Exp Gerontol. 2017;100:28\u201335. https:\/\/doi.org\/10.1016\/j.exger.2017.10.012.","journal-title":"Exp Gerontol"},{"key":"1621_CR236","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/sj.bjp.0704549","volume":"135","author":"DJ MacEwan","year":"2002","unstructured":"MacEwan DJ. TNF ligands and receptors\u2013a matter of life and death. Br J Pharmacol. 2002;135:855\u201375. https:\/\/doi.org\/10.1038\/sj.bjp.0704549.","journal-title":"Br J Pharmacol"},{"key":"1621_CR237","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1126\/science.1071924","volume":"296","author":"G Chen","year":"2002","unstructured":"Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science. 2002;296:1634\u20135. https:\/\/doi.org\/10.1126\/science.1071924.","journal-title":"Science"},{"key":"1621_CR238","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cytogfr.2014.03.004","volume":"25","author":"L Puim\u00e8ge","year":"2014","unstructured":"Puim\u00e8ge L, Libert C, Van Hauwermeiren F. Regulation and dysregulation of tumor necrosis factor receptor-1. Cytokine Growth Factor Rev. 2014;25:285\u2013300. https:\/\/doi.org\/10.1016\/j.cytogfr.2014.03.004.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1621_CR239","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41584-021-00639-6","volume":"17","author":"BL Salomon","year":"2021","unstructured":"Salomon BL. Insights into the biology and therapeutic implications of TNF and regulatory T cells. Nat Rev Rheumatol. 2021;17:487\u2013504. https:\/\/doi.org\/10.1038\/s41584-021-00639-6.","journal-title":"Nat Rev Rheumatol"},{"key":"1621_CR240","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.it.2016.06.002","volume":"37","author":"AT Ting","year":"2016","unstructured":"Ting AT, Bertrand MJM. More to Life than NF-\u03baB in TNFR1 Signaling. Trends Immunol. 2016;37:535\u201345. https:\/\/doi.org\/10.1016\/j.it.2016.06.002.","journal-title":"Trends Immunol"},{"key":"1621_CR241","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.cytogfr.2011.09.004","volume":"22","author":"F Van Hauwermeiren","year":"2011","unstructured":"Van Hauwermeiren F, Vandenbroucke RE, Libert C. Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine Growth Factor Rev. 2011;22:311\u20139. https:\/\/doi.org\/10.1016\/j.cytogfr.2011.09.004.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1621_CR242","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/jlb.2mr0120-510r","volume":"107","author":"KN Atretkhany","year":"2020","unstructured":"Atretkhany KN, Gogoleva VS, Drutskaya MS, Nedospasov SA. Distinct modes of TNF signaling through its two receptors in health and disease. J Leukoc Biol. 2020;107:893\u2013905. https:\/\/doi.org\/10.1002\/jlb.2mr0120-510r.","journal-title":"J Leukoc Biol"},{"issue":"Suppl 1","key":"1621_CR243","doi-asserted-by":"publisher","first-page":"i50","DOI":"10.1136\/ard.59.suppl_1.i50","volume":"59","author":"FK Chan","year":"2000","unstructured":"Chan FK. The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function. Ann Rheum Dis. 2000;59(Suppl 1):i50-53. https:\/\/doi.org\/10.1136\/ard.59.suppl_1.i50.","journal-title":"Ann Rheum Dis"},{"key":"1621_CR244","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/14728222.2019.1586886","volume":"23","author":"J Medler","year":"2019","unstructured":"Medler J, Wajant H. Tumor necrosis factor receptor-2 (TNFR2): an overview of an emerging drug target. Expert Opin Ther Targets. 2019;23:295\u2013307. https:\/\/doi.org\/10.1080\/14728222.2019.1586886.","journal-title":"Expert Opin Ther Targets"},{"key":"1621_CR245","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/j.1742-4658.2011.08017.x","volume":"278","author":"PJ Naud\u00e9","year":"2011","unstructured":"Naud\u00e9 PJ, den Boer JA, Luiten PG, Eisel UL. Tumor necrosis factor receptor cross-talk. Febs j. 2011;278:888\u201398. https:\/\/doi.org\/10.1111\/j.1742-4658.2011.08017.x.","journal-title":"Febs j"},{"key":"1621_CR246","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1146\/annurev-pathol-020117-043625","volume":"13","author":"H Al-Samkari","year":"2018","unstructured":"Al-Samkari H, Berliner N. Hemophagocytic Lymphohistiocytosis. Annu Rev Pathol. 2018;13:27\u201349. https:\/\/doi.org\/10.1146\/annurev-pathol-020117-043625.","journal-title":"Annu Rev Pathol"},{"key":"1621_CR247","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.cytogfr.2014.10.001","volume":"26","author":"E Brisse","year":"2015","unstructured":"Brisse E, Wouters CH, Matthys P. Hemophagocytic lymphohistiocytosis (HLH): a heterogeneous spectrum of cytokine-driven immune disorders. Cytokine Growth Factor Rev. 2015;26:263\u201380. https:\/\/doi.org\/10.1016\/j.cytogfr.2014.10.001.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1621_CR248","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/s0140-6736(13)61048-x","volume":"383","author":"M Ramos-Casals","year":"2014","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, L\u00f3pez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383:1503\u201316. https:\/\/doi.org\/10.1016\/s0140-6736(13)61048-x.","journal-title":"Lancet"},{"key":"1621_CR249","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23137191","author":"YW Duan","year":"2022","unstructured":"Duan YW, Chen SX, Li QY, Zang Y. Neuroimmune mechanisms underlying neuropathic pain: the potential role of TNF-\u03b1-necroptosis pathway. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23137191.","journal-title":"Int J Mol Sci"},{"key":"1621_CR250","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.tcb.2015.01.001","volume":"25","author":"K Newton","year":"2015","unstructured":"Newton K. RIPK1 and RIPK3: critical regulators of inflammation and cell death. Trends Cell Biol. 2015;25:347\u201353. https:\/\/doi.org\/10.1016\/j.tcb.2015.01.001.","journal-title":"Trends Cell Biol"},{"key":"1621_CR251","doi-asserted-by":"publisher","first-page":"1074440","DOI":"10.3389\/fimmu.2022.1074440","volume":"13","author":"F Pinci","year":"2022","unstructured":"Pinci F, et al. Tumor necrosis factor is a necroptosis-associated alarmin. Front Immunol. 2022;13:1074440. https:\/\/doi.org\/10.3389\/fimmu.2022.1074440.","journal-title":"Front Immunol"},{"key":"1621_CR252","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41577-022-00792-3","volume":"23","author":"G van Loo","year":"2023","unstructured":"van Loo G, Bertrand MJM. Death by TNF: a road to inflammation. Nat Rev Immunol. 2023;23:289\u2013303. https:\/\/doi.org\/10.1038\/s41577-022-00792-3.","journal-title":"Nat Rev Immunol"},{"key":"1621_CR253","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41419-022-04883-w","volume":"13","author":"A M\u00e1zl\u00f3","year":"2022","unstructured":"M\u00e1zl\u00f3 A, et al. Types of necroinflammation, the effect of cell death modalities on sterile inflammation. Cell Death Dis. 2022;13:423. https:\/\/doi.org\/10.1038\/s41419-022-04883-w.","journal-title":"Cell Death Dis"},{"key":"1621_CR254","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-020-00946-7","volume":"13","author":"R Tang","year":"2020","unstructured":"Tang R, et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J Hematol Oncol. 2020;13:110. https:\/\/doi.org\/10.1186\/s13045-020-00946-7.","journal-title":"J Hematol Oncol"},{"key":"1621_CR255","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc3465","author":"B Demarco","year":"2020","unstructured":"Demarco B, et al. Caspase-8-dependent gasdermin D cleavage promotes antimicrobial defense but confers susceptibility to TNF-induced lethality. Sci Adv. 2020. https:\/\/doi.org\/10.1126\/sciadv.abc3465.","journal-title":"Sci Adv"},{"key":"1621_CR256","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.molcel.2015.07.032","volume":"60","author":"Y Dondelinger","year":"2015","unstructured":"Dondelinger Y, et al. NF-\u03baB-Independent Role of IKK\u03b1\/IKK\u03b2 in Preventing RIPK1 Kinase-Dependent Apoptotic and Necroptotic Cell Death during TNF Signaling. Mol Cell. 2015;60:63\u201376. https:\/\/doi.org\/10.1016\/j.molcel.2015.07.032.","journal-title":"Mol Cell"},{"key":"1621_CR257","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/s41556-018-0229-6","volume":"20","author":"E Lafont","year":"2018","unstructured":"Lafont E, et al. TBK1 and IKK\u03b5 prevent TNF-induced cell death by RIPK1 phosphorylation. Nat Cell Biol. 2018;20:1389\u201399. https:\/\/doi.org\/10.1038\/s41556-018-0229-6.","journal-title":"Nat Cell Biol"},{"key":"1621_CR258","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/s0092-8674(03)00521-x","volume":"114","author":"O Micheau","year":"2003","unstructured":"Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114:181\u201390. https:\/\/doi.org\/10.1016\/s0092-8674(03)00521-x.","journal-title":"Cell"},{"key":"1621_CR259","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2008.03.036","volume":"133","author":"L Wang","year":"2008","unstructured":"Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell. 2008;133:693\u2013703. https:\/\/doi.org\/10.1016\/j.cell.2008.03.036.","journal-title":"Cell"},{"key":"1621_CR260","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.3389\/fimmu.2018.02572","volume":"9","author":"S Ahmad","year":"2018","unstructured":"Ahmad S, et al. The key role of TNF-TNFR2 interactions in the modulation of allergic inflammation: a review. Front Immunol. 2018;9:2572. https:\/\/doi.org\/10.3389\/fimmu.2018.02572.","journal-title":"Front Immunol"},{"key":"1621_CR261","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/path.2287","volume":"214","author":"JR Bradley","year":"2008","unstructured":"Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214:149\u201360. https:\/\/doi.org\/10.1002\/path.2287.","journal-title":"J Pathol"},{"key":"1621_CR262","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.903913","volume":"13","author":"A Kouyoumdjian","year":"2022","unstructured":"Kouyoumdjian A, Tchervenkov J, Paraskevas S. TFNR2 in ischemia-reperfusion injury, rejection, and tolerance in transplantation. Front Immunol. 2022;13: 903913. https:\/\/doi.org\/10.3389\/fimmu.2022.903913.","journal-title":"Front Immunol"},{"key":"1621_CR263","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12929-017-0398-9","volume":"24","author":"I Mart\u00ednez-Reza","year":"2017","unstructured":"Mart\u00ednez-Reza I, D\u00edaz L, Garc\u00eda-Becerra R. Preclinical and clinical aspects of TNF-\u03b1 and its receptors TNFR1 and TNFR2 in breast cancer. J Biomed Sci. 2017;24:90. https:\/\/doi.org\/10.1186\/s12929-017-0398-9.","journal-title":"J Biomed Sci"},{"key":"1621_CR264","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.3389\/fimmu.2019.02040","volume":"10","author":"H Wajant","year":"2019","unstructured":"Wajant H, Beilhack A. Targeting regulatory T Cells by addressing tumor necrosis factor and its receptors in allogeneic hematopoietic cell transplantation and cancer. Front Immunol. 2019;10:2040. https:\/\/doi.org\/10.3389\/fimmu.2019.02040.","journal-title":"Front Immunol"},{"key":"1621_CR265","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3389\/fimmu.2018.00784","volume":"9","author":"S Yang","year":"2018","unstructured":"Yang S, Wang J, Brand DD, Zheng SG. Role of TNF-TNF receptor 2 signal in regulatory T cells and its therapeutic implications. Front Immunol. 2018;9:784. https:\/\/doi.org\/10.3389\/fimmu.2018.00784.","journal-title":"Front Immunol"},{"key":"1621_CR266","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3389\/fimmu.2013.00139","volume":"4","author":"T So","year":"2013","unstructured":"So T, Croft M. Regulation of PI-3-kinase and akt signaling in T lymphocytes and other cells by TNFR family molecules. Front Immunol. 2013;4:139. https:\/\/doi.org\/10.3389\/fimmu.2013.00139.","journal-title":"Front Immunol"},{"key":"1621_CR267","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/cmi.2017.138","volume":"16","author":"V Lamontain","year":"2019","unstructured":"Lamontain V, et al. Stimulation of TNF receptor type 2 expands regulatory T cells and ameliorates established collagen-induced arthritis in mice. Cell Mol Immunol. 2019;16:65\u201374. https:\/\/doi.org\/10.1038\/cmi.2017.138.","journal-title":"Cell Mol Immunol"},{"key":"1621_CR268","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1182\/blood-2016-02-700849","volume":"128","author":"M Leclerc","year":"2016","unstructured":"Leclerc M, et al. Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells. Blood. 2016;128:1651\u20139. https:\/\/doi.org\/10.1182\/blood-2016-02-700849.","journal-title":"Blood"},{"key":"1621_CR269","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/s41375-018-0292-9","volume":"33","author":"H Torrey","year":"2019","unstructured":"Torrey H, et al. Targeted killing of TNFR2-expressing tumor cells and T(regs) by TNFR2 antagonistic antibodies in advanced S\u00e9zary syndrome. Leukemia. 2019;33:1206\u201318. https:\/\/doi.org\/10.1038\/s41375-018-0292-9.","journal-title":"Leukemia"},{"key":"1621_CR270","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.3389\/fimmu.2018.01382","volume":"9","author":"F Shaikh","year":"2018","unstructured":"Shaikh F, He J, Bhadra P, Chen X, Siu SWI. TNF Receptor type II as an emerging drug target for the treatment of cancer, autoimmune diseases, and graft-versus-host disease: current perspectives and in silico search for small molecule binders. Front Immunol. 2018;9:1382. https:\/\/doi.org\/10.3389\/fimmu.2018.01382.","journal-title":"Front Immunol"},{"key":"1621_CR271","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.3389\/fimmu.2018.01170","volume":"9","author":"Y Sheng","year":"2018","unstructured":"Sheng Y, Li F, Qin Z. TNF receptor 2 makes tumor necrosis factor a friend of tumors. Front Immunol. 2018;9:1170. https:\/\/doi.org\/10.3389\/fimmu.2018.01170.","journal-title":"Front Immunol"},{"key":"1621_CR272","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1172\/jci64115","volume":"122","author":"X Zhao","year":"2012","unstructured":"Zhao X, et al. TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest. 2012;122:4094\u2013104. https:\/\/doi.org\/10.1172\/jci64115.","journal-title":"J Clin Invest"},{"key":"1621_CR273","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.cytogfr.2019.05.001","volume":"47","author":"A Mancusi","year":"2019","unstructured":"Mancusi A, Alvarez M, Piccinelli S, Velardi A, Pierini A. TNFR2 signaling modulates immunity after allogeneic hematopoietic cell transplantation. Cytokine Growth Factor Rev. 2019;47:54\u201361. https:\/\/doi.org\/10.1016\/j.cytogfr.2019.05.001.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1621_CR274","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/art.41134","volume":"72","author":"F Santinon","year":"2020","unstructured":"Santinon F, et al. Involvement of Tumor necrosis factor receptor type II in FoxP3 stability and as a marker of treg cells specifically expanded by anti-tumor necrosis factor treatments in rheumatoid arthritis. Arthritis Rheumatol. 2020;72:576\u201387. https:\/\/doi.org\/10.1002\/art.41134.","journal-title":"Arthritis Rheumatol"},{"key":"1621_CR275","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jaci.2015.12.1314","volume":"138","author":"S Humblet-Baron","year":"2016","unstructured":"Humblet-Baron S, et al. IL-2 consumption by highly activated CD8 T cells induces regulatory T-cell dysfunction in patients with hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol. 2016;138:200-209.e208. https:\/\/doi.org\/10.1016\/j.jaci.2015.12.1314.","journal-title":"J Allergy Clin Immunol"},{"key":"1621_CR276","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/gut.49.1.131","volume":"49","author":"X Bo","year":"2001","unstructured":"Bo X, Broome U, Remberger M, Sumitran-Holgersson S. Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis. Gut. 2001;49:131\u201341. https:\/\/doi.org\/10.1136\/gut.49.1.131.","journal-title":"Gut"},{"key":"1621_CR277","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1182\/blood.V72.1.344.344","volume":"72","author":"A Kist","year":"1988","unstructured":"Kist A, et al. Decrease of natural killer cell activity and monokine production in peripheral blood of patients treated with recombinant tumor necrosis factor. Blood. 1988;72:344\u20138.","journal-title":"Blood"},{"key":"1621_CR278","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1182\/blood.2019003664","volume":"136","author":"J Carvelli","year":"2020","unstructured":"Carvelli J, et al. Functional and genetic testing in adults with HLH reveals an inflammatory profile rather than a cytotoxicity defect. Blood. 2020;136:542\u201352. https:\/\/doi.org\/10.1182\/blood.2019003664.","journal-title":"Blood"},{"key":"1621_CR279","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-med-042921-112837","volume":"74","author":"RQ Cron","year":"2023","unstructured":"Cron RQ, Goyal G, Chatham WW. Cytokine storm syndrome. Annu Rev Med. 2023;74:321\u201337. https:\/\/doi.org\/10.1146\/annurev-med-042921-112837.","journal-title":"Annu Rev Med"},{"key":"1621_CR280","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2007","unstructured":"Henter JI, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124\u201331. https:\/\/doi.org\/10.1002\/pbc.21039.","journal-title":"Pediatr Blood Cancer"},{"key":"1621_CR281","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev-med-041610-134208","volume":"63","author":"GE Janka","year":"2012","unstructured":"Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med. 2012;63:233\u201346. https:\/\/doi.org\/10.1146\/annurev-med-041610-134208.","journal-title":"Annu Rev Med"},{"key":"1621_CR282","doi-asserted-by":"publisher","first-page":"414","DOI":"10.4414\/smw.2002.10031","volume":"132","author":"D Aeberli","year":"2002","unstructured":"Aeberli D, et al. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly. 2002;132:414\u201322. https:\/\/doi.org\/10.4414\/smw.2002.10031.","journal-title":"Swiss Med Wkly"},{"key":"1621_CR283","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/pbc.21019","volume":"50","author":"B Makay","year":"2008","unstructured":"Makay B, et al. Etanercept for therapy-resistant macrophage activation syndrome. Pediatr Blood Cancer. 2008;50:419\u201321. https:\/\/doi.org\/10.1002\/pbc.21019.","journal-title":"Pediatr Blood Cancer"},{"key":"1621_CR284","first-page":"2120","volume":"28","author":"S Prahalad","year":"2001","unstructured":"Prahalad S, Bove KE, Dickens D, Lovell DJ, Grom AA. Etanercept in the treatment of macrophage activation syndrome. J Rheumatol. 2001;28:2120\u20134.","journal-title":"J Rheumatol"},{"key":"1621_CR285","first-page":"401","volume":"30","author":"AV Ramanan","year":"2003","unstructured":"Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2003;30:401\u20133.","journal-title":"J Rheumatol"},{"key":"1621_CR286","first-page":"241","volume":"34","author":"C Sandhu","year":"2007","unstructured":"Sandhu C, Chesney A, Piliotis E, Buckstein R, Koren S. Macrophage activation syndrome after etanercept treatment. J Rheumatol. 2007;34:241\u20132.","journal-title":"J Rheumatol"},{"key":"1621_CR287","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12969-022-00735-1","volume":"20","author":"N Aslani","year":"2022","unstructured":"Aslani N, et al. TNFAIP3 mutation causing haploinsufficiency of A20 with a hemophagocytic lymphohistiocytosis phenotype: a report of two cases. Pediatr Rheumatol Online J. 2022;20:78. https:\/\/doi.org\/10.1186\/s12969-022-00735-1.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1621_CR288","first-page":"1414","volume":"16","author":"M Atteritano","year":"2012","unstructured":"Atteritano M, et al. Haemophagocytic syndrome in rheumatic patients: a systematic review. Eur Rev Med Pharmacol Sci. 2012;16:1414\u201324.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1621_CR289","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/00124743-200108000-00013","volume":"7","author":"A Stern","year":"2001","unstructured":"Stern A, Riley R, Buckley L. Worsening of macrophage activation syndrome in a patient with adult onset Still\u2019s disease after initiation of etanercept therapy. J Clin Rheumatol. 2001;7:252\u20136. https:\/\/doi.org\/10.1097\/00124743-200108000-00013.","journal-title":"J Clin Rheumatol"},{"key":"1621_CR290","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10067-018-4387-5","volume":"38","author":"R Baker","year":"2019","unstructured":"Baker R, Liew JW, Simonson PD, Soma LA, Starkebaum G. Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab. Clin Rheumatol. 2019;38:603\u20138. https:\/\/doi.org\/10.1007\/s10067-018-4387-5.","journal-title":"Clin Rheumatol"},{"key":"1621_CR291","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/s0755-4982(05)83984-3","volume":"34","author":"E Chauveau","year":"2005","unstructured":"Chauveau E, Terrier F, Casassus-Buihle D, Moncoucy X, Oddes B. Macrophage activation syndrome after treatment with infliximab for fistulated Crohn\u2019s disease. Presse Med. 2005;34:583\u20134. https:\/\/doi.org\/10.1016\/s0755-4982(05)83984-3.","journal-title":"Presse Med"},{"key":"1621_CR292","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","volume":"117","author":"CA Dinarello","year":"2011","unstructured":"Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117:3720\u201332. https:\/\/doi.org\/10.1182\/blood-2010-07-273417.","journal-title":"Blood"},{"key":"1621_CR293","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12621","volume":"281","author":"CA Dinarello","year":"2018","unstructured":"Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281:8\u201327. https:\/\/doi.org\/10.1111\/imr.12621.","journal-title":"Immunol Rev"},{"key":"1621_CR294","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1089\/jir.2022.0185","volume":"43","author":"M Ghofrani Nezhad","year":"2023","unstructured":"Ghofrani Nezhad M, Jami G, Kooshkaki O, Chamani S, Naghizadeh A. The role of inflammatory cytokines (interleukin-1 and interleukin-6) as a potential biomarker in the different stages of COVID-19 (mild, severe, and critical). J Interferon Cytokine Res. 2023;43:147\u201363. https:\/\/doi.org\/10.1089\/jir.2022.0185.","journal-title":"J Interferon Cytokine Res"},{"key":"1621_CR295","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/s1359-6101(02)00020-5","volume":"13","author":"WP Arend","year":"2002","unstructured":"Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002;13:323\u201340. https:\/\/doi.org\/10.1016\/s1359-6101(02)00020-5.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1621_CR296","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.semcancer.2022.05.002","volume":"86","author":"R Sun","year":"2022","unstructured":"Sun R, Gao DS, Shoush J, Lu B. The IL-1 family in tumorigenesis and antitumor immunity. Semin Cancer Biol. 2022;86:280\u201395. https:\/\/doi.org\/10.1016\/j.semcancer.2022.05.002.","journal-title":"Semin Cancer Biol"},{"key":"1621_CR297","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.immuni.2015.06.003","volume":"42","author":"IS Afonina","year":"2015","unstructured":"Afonina IS, M\u00fcller C, Martin SJ, Beyaert R. Proteolytic processing of interleukin-1 family cytokines: variations on a common theme. Immunity. 2015;42:991\u20131004. https:\/\/doi.org\/10.1016\/j.immuni.2015.06.003.","journal-title":"Immunity"},{"key":"1621_CR298","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-immunol-032414-112306","volume":"33","author":"MG Netea","year":"2015","unstructured":"Netea MG, van de Veerdonk FL, van der Meer JW, Dinarello CA, Joosten LA. Inflammasome-independent regulation of IL-1-family cytokines. Annu Rev Immunol. 2015;33:49\u201377. https:\/\/doi.org\/10.1146\/annurev-immunol-032414-112306.","journal-title":"Annu Rev Immunol"},{"key":"1621_CR299","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.cytogfr.2014.04.003","volume":"25","author":"M Aguilera","year":"2014","unstructured":"Aguilera M, Darby T, Melgar S. The complex role of inflammasomes in the pathogenesis of Inflammatory Bowel Diseases: lessons learned from experimental models. Cytokine Growth Factor Rev. 2014;25:715\u201330. https:\/\/doi.org\/10.1016\/j.cytogfr.2014.04.003.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1621_CR300","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jhep.2013.03.033","volume":"59","author":"C Brenner","year":"2013","unstructured":"Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol. 2013;59:583\u201394. https:\/\/doi.org\/10.1016\/j.jhep.2013.03.033.","journal-title":"J Hepatol"},{"key":"1621_CR301","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/ni.3503","volume":"17","author":"NC Di Paolo","year":"2016","unstructured":"Di Paolo NC, Shayakhmetov DM. Interleukin 1\u03b1 and the inflammatory process. Nat Immunol. 2016;17:906\u201313. https:\/\/doi.org\/10.1038\/ni.3503.","journal-title":"Nat Immunol"},{"key":"1621_CR302","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.immuni.2015.07.007","volume":"43","author":"H Hammad","year":"2015","unstructured":"Hammad H, Lambrecht BN. Barrier epithelial cells and the control of type 2 immunity. Immunity. 2015;43:29\u201340. https:\/\/doi.org\/10.1016\/j.immuni.2015.07.007.","journal-title":"Immunity"},{"key":"1621_CR303","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1172\/jci93537","volume":"127","author":"SS Weigt","year":"2017","unstructured":"Weigt SS, Palchevskiy V, Belperio JA. Inflammasomes and IL-1 biology in the pathogenesis of allograft dysfunction. J Clin Invest. 2017;127:2022\u20139. https:\/\/doi.org\/10.1172\/jci93537.","journal-title":"J Clin Invest"},{"key":"1621_CR304","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13045-023-01407-7","volume":"16","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Li X, Wang Y, Wei Y, Wei X. Involvement of inflammasomes in tumor microenvironment and tumor therapies. J Hematol Oncol. 2023;16:24. https:\/\/doi.org\/10.1186\/s13045-023-01407-7.","journal-title":"J Hematol Oncol"},{"key":"1621_CR305","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.ccell.2021.04.011","volume":"39","author":"C Garlanda","year":"2021","unstructured":"Garlanda C, Mantovani A. Interleukin-1 in tumor progression, therapy, and prevention. Cancer Cell. 2021;39:1023\u20137. https:\/\/doi.org\/10.1016\/j.ccell.2021.04.011.","journal-title":"Cancer Cell"},{"key":"1621_CR306","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clim.2018.10.016","volume":"206","author":"JS Hausmann","year":"2019","unstructured":"Hausmann JS. Targeting cytokines to treat autoinflammatory diseases. Clin Immunol. 2019;206:23\u201332. https:\/\/doi.org\/10.1016\/j.clim.2018.10.016.","journal-title":"Clin Immunol"},{"key":"1621_CR307","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrrheum.2015.79","volume":"11","author":"D Holzinger","year":"2015","unstructured":"Holzinger D, Kessel C, Omenetti A, Gattorno M. From bench to bedside and back again: translational research in autoinflammation. Nat Rev Rheumatol. 2015;11:573\u201385. https:\/\/doi.org\/10.1038\/nrrheum.2015.79.","journal-title":"Nat Rev Rheumatol"},{"key":"1621_CR308","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.614704","volume":"12","author":"C Keenan","year":"2021","unstructured":"Keenan C, Nichols KE, Albeituni S. Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis. Front Immunol. 2021;12: 614704. https:\/\/doi.org\/10.3389\/fimmu.2021.614704.","journal-title":"Front Immunol"},{"key":"1621_CR309","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nri2691","volume":"10","author":"JE Sims","year":"2010","unstructured":"Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010;10:89\u2013102. https:\/\/doi.org\/10.1038\/nri2691.","journal-title":"Nat Rev Immunol"},{"key":"1621_CR310","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrrheum.2010.4","volume":"6","author":"C Gabay","year":"2010","unstructured":"Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol. 2010;6:232\u201341. https:\/\/doi.org\/10.1038\/nrrheum.2010.4.","journal-title":"Nat Rev Rheumatol"},{"key":"1621_CR311","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.it.2011.01.003","volume":"32","author":"FL van de Veerdonk","year":"2011","unstructured":"van de Veerdonk FL, Netea MG, Dinarello CA, Joosten LA. Inflammasome activation and IL-1\u03b2 and IL-18 processing during infection. Trends Immunol. 2011;32:110\u20136. https:\/\/doi.org\/10.1016\/j.it.2011.01.003.","journal-title":"Trends Immunol"},{"key":"1621_CR312","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1053\/j.gastro.2011.02.016","volume":"140","author":"W Strober","year":"2011","unstructured":"Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140:1756\u201367. https:\/\/doi.org\/10.1053\/j.gastro.2011.02.016.","journal-title":"Gastroenterology"},{"key":"1621_CR313","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1002\/art.22981","volume":"56","author":"N Fall","year":"2007","unstructured":"Fall N, et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 2007;56:3793\u2013804. https:\/\/doi.org\/10.1002\/art.22981.","journal-title":"Arthritis Rheum"},{"key":"1621_CR314","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3389\/fimmu.2013.00351","volume":"4","author":"S Federici","year":"2013","unstructured":"Federici S, Martini A, Gattorno M. The central role of anti-IL-1 blockade in the treatment of monogenic and multi-factorial autoinflammatory diseases. Front Immunol. 2013;4:351. https:\/\/doi.org\/10.3389\/fimmu.2013.00351.","journal-title":"Front Immunol"},{"key":"1621_CR315","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1002\/pmic.201000298","volume":"10","author":"XB Ling","year":"2010","unstructured":"Ling XB, et al. Plasma profiles in active systemic juvenile idiopathic arthritis: biomarkers and biological implications. Proteomics. 2010;10:4415\u201330. https:\/\/doi.org\/10.1002\/pmic.201000298.","journal-title":"Proteomics"},{"key":"1621_CR316","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1084\/jem.20050473","volume":"201","author":"V Pascual","year":"2005","unstructured":"Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201:1479\u201386. https:\/\/doi.org\/10.1084\/jem.20050473.","journal-title":"J Exp Med"},{"key":"1621_CR317","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/art.21061","volume":"52","author":"AA Fitzgerald","year":"2005","unstructured":"Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still\u2019s disease. Arthritis Rheum. 2005;52:1794\u2013803. https:\/\/doi.org\/10.1002\/art.21061.","journal-title":"Arthritis Rheum"},{"key":"1621_CR318","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrrheum.2013.174","volume":"10","author":"S Ozen","year":"2014","unstructured":"Ozen S, Bilginer Y. A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol. 2014;10:135\u201347. https:\/\/doi.org\/10.1038\/nrrheum.2013.174.","journal-title":"Nat Rev Rheumatol"},{"key":"1621_CR319","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1136\/annrheumdis-2021-221801","volume":"81","author":"M Romano","year":"2022","unstructured":"Romano M, et al. The 2021 EULAR\/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Ann Rheum Dis. 2022;81:907\u201321. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221801.","journal-title":"Ann Rheum Dis"},{"key":"1621_CR320","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","volume":"10","author":"CB Crayne","year":"2019","unstructured":"Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front Immunol. 2019;10:119. https:\/\/doi.org\/10.3389\/fimmu.2019.00119.","journal-title":"Front Immunol"},{"key":"1621_CR321","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.smim.2013.10.008","volume":"25","author":"CA Dinarello","year":"2013","unstructured":"Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;25:469\u201384. https:\/\/doi.org\/10.1016\/j.smim.2013.10.008.","journal-title":"Semin Immunol"},{"key":"1621_CR322","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3899\/jrheum.091046","volume":"37","author":"M Durand","year":"2010","unstructured":"Durand M, Troyanov Y, Laflamme P, Gregoire G. Macrophage activation syndrome treated with anakinra. J Rheumatol. 2010;37:879\u201380. https:\/\/doi.org\/10.3899\/jrheum.091046.","journal-title":"J Rheumatol"},{"key":"1621_CR323","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/art.23437","volume":"58","author":"M Gattorno","year":"2008","unstructured":"Gattorno M, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008;58:1505\u201315. https:\/\/doi.org\/10.1002\/art.23437.","journal-title":"Arthritis Rheum"},{"key":"1621_CR324","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","volume":"50","author":"PM Miettunen","year":"2011","unstructured":"Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford). 2011;50:417\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keq218.","journal-title":"Rheumatology (Oxford)"},{"key":"1621_CR325","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/art.30128","volume":"63","author":"PA Nigrovic","year":"2011","unstructured":"Nigrovic PA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63:545\u201355. https:\/\/doi.org\/10.1002\/art.30128.","journal-title":"Arthritis Rheum"},{"key":"1621_CR326","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/RHU.0b013e3181a4f459","volume":"15","author":"A Zeft","year":"2009","unstructured":"Zeft A, et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol. 2009;15:161\u20134. https:\/\/doi.org\/10.1097\/RHU.0b013e3181a4f459.","journal-title":"J Clin Rheumatol"},{"key":"1621_CR327","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/ccm.0000000000001402","volume":"44","author":"B Shakoory","year":"2016","unstructured":"Shakoory B, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2016;44:275\u201381. https:\/\/doi.org\/10.1097\/ccm.0000000000001402.","journal-title":"Crit Care Med"},{"key":"1621_CR328","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.chom.2020.05.007","volume":"28","author":"G Dimopoulos","year":"2020","unstructured":"Dimopoulos G, et al. Favorable anakinra responses in severe Covid-19 patients with secondary hemophagocytic lymphohistiocytosis. Cell Host Microbe. 2020;28:117-123.e111. https:\/\/doi.org\/10.1016\/j.chom.2020.05.007.","journal-title":"Cell Host Microbe"},{"key":"1621_CR329","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40259-015-0123-8","volume":"29","author":"SM Hoy","year":"2015","unstructured":"Hoy SM. Canakinumab: a review of its use in the management of systemic juvenile idiopathic arthritis. BioDrugs. 2015;29:133\u201342. https:\/\/doi.org\/10.1007\/s40259-015-0123-8.","journal-title":"BioDrugs"},{"key":"1621_CR330","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/adc.85.5.421","volume":"85","author":"S Sawhney","year":"2001","unstructured":"Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001;85:421\u20136. https:\/\/doi.org\/10.1136\/adc.85.5.421.","journal-title":"Arch Dis Child"},{"key":"1621_CR331","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/art.39407","volume":"68","author":"AA Grom","year":"2016","unstructured":"Grom AA, et al. Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab. Arthritis Rheumatol. 2016;68:218\u201328. https:\/\/doi.org\/10.1002\/art.39407.","journal-title":"Arthritis Rheumatol"},{"key":"1621_CR332","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396\u2013406. https:\/\/doi.org\/10.1056\/NEJMoa1205099.","journal-title":"N Engl J Med"},{"key":"1621_CR333","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107606","volume":"96","author":"GQ Meng","year":"2021","unstructured":"Meng GQ, Wang JS, Wang YN, Wei N, Wang Z. Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infection. Int Immunopharmacol. 2021;96: 107606. https:\/\/doi.org\/10.1016\/j.intimp.2021.107606.","journal-title":"Int Immunopharmacol"},{"key":"1621_CR334","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.930141","volume":"13","author":"H Miyazawa","year":"2022","unstructured":"Miyazawa H, Wada T. Immune-mediated inflammatory diseases with chronic excess of serum interleukin-18. Front Immunol. 2022;13: 930141. https:\/\/doi.org\/10.3389\/fimmu.2022.930141.","journal-title":"Front Immunol"},{"key":"1621_CR335","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1586\/1744666X.1.4.619","volume":"1","author":"CA Dinarello","year":"2005","unstructured":"Dinarello CA, Kaplanski G. Interleukin-18 treatment options for inflammatory diseases. Expert Rev Clin Immunol. 2005;1:619\u201332. https:\/\/doi.org\/10.1586\/1744666X.1.4.619.","journal-title":"Expert Rev Clin Immunol"},{"key":"1621_CR336","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/imr.12616","volume":"281","author":"G Kaplanski","year":"2018","unstructured":"Kaplanski G. Interleukin-18: biological properties and role in disease pathogenesis. Immunol Rev. 2018;281:138\u201353. https:\/\/doi.org\/10.1111\/imr.12616.","journal-title":"Immunol Rev"},{"key":"1621_CR337","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2019.109388","volume":"63","author":"H M\u00fchl","year":"2019","unstructured":"M\u00fchl H, Bachmann M. IL-18\/IL-18BP and IL-22\/IL-22BP: two interrelated couples with therapeutic potential. Cell Signal. 2019;63: 109388. https:\/\/doi.org\/10.1016\/j.cellsig.2019.109388.","journal-title":"Cell Signal"},{"key":"1621_CR338","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/s0091-6749(99)70518-x","volume":"103","author":"CA Dinarello","year":"1999","unstructured":"Dinarello CA. IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol. 1999;103:11\u201324. https:\/\/doi.org\/10.1016\/s0091-6749(99)70518-x.","journal-title":"J Allergy Clin Immunol"},{"key":"1621_CR339","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41586-020-2422-6","volume":"583","author":"T Zhou","year":"2020","unstructured":"Zhou T, et al. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature. 2020;583:609\u201314. https:\/\/doi.org\/10.1038\/s41586-020-2422-6.","journal-title":"Nature"},{"key":"1621_CR340","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00763","author":"K Nakanishi","year":"2018","unstructured":"Nakanishi K. Unique action of interleukin-18 on T cells and other immune cells. Front Immunol. 2018. https:\/\/doi.org\/10.3389\/fimmu.2018.00763.","journal-title":"Front Immunol"},{"key":"1621_CR341","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.639103","author":"Y Hirooka","year":"2021","unstructured":"Hirooka Y, Nozaki Y. Interleukin-18 in inflammatory kidney disease. Front Med. 2021. https:\/\/doi.org\/10.3389\/fmed.2021.639103.","journal-title":"Front Med"},{"key":"1621_CR342","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1146\/annurev.immunol.19.1.423","volume":"19","author":"K Nakanishi","year":"2001","unstructured":"Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol. 2001;19:423\u201374. https:\/\/doi.org\/10.1146\/annurev.immunol.19.1.423.","journal-title":"Annu Rev Immunol"},{"key":"1621_CR343","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.4049\/jimmunol.162.3.1662","volume":"162","author":"Y Hyodo","year":"1999","unstructured":"Hyodo Y, et al. IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor. J Immunol. 1999;162:1662\u20138.","journal-title":"J Immunol"},{"key":"1621_CR344","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.jaci.2022.06.017","volume":"150","author":"Y Tang","year":"2022","unstructured":"Tang Y, et al. Excessive IL-10 and IL-18 trigger hemophagocytic lymphohistiocytosis-like hyperinflammation and enhanced myelopoiesis. J Allergy Clin Immunol. 2022;150:1154\u201367. https:\/\/doi.org\/10.1016\/j.jaci.2022.06.017.","journal-title":"J Allergy Clin Immunol"},{"key":"1621_CR345","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1046\/j.1365-2141.1999.01504.x","volume":"106","author":"H Takada","year":"1999","unstructured":"Takada H, et al. Oversecretion of IL-18 in haemophagocytic lymphohistiocytosis: a novel marker of disease activity. Br J Haematol. 1999;106:182\u20139. https:\/\/doi.org\/10.1046\/j.1365-2141.1999.01504.x.","journal-title":"Br J Haematol"},{"key":"1621_CR346","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.4049\/jimmunol.158.4.1541","volume":"158","author":"K Kohno","year":"1997","unstructured":"Kohno K, et al. IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol. 1997;158:1541\u201350.","journal-title":"J Immunol"},{"key":"1621_CR347","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1182\/blood-2005-05-1980","volume":"106","author":"K Mazodier","year":"2005","unstructured":"Mazodier K, et al. Severe imbalance of IL-18\/IL-18BP in patients with secondary hemophagocytic syndrome. Blood. 2005;106:3483\u20139. https:\/\/doi.org\/10.1182\/blood-2005-05-1980.","journal-title":"Blood"},{"key":"1621_CR348","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/cei.13543","volume":"203","author":"JM Krei","year":"2021","unstructured":"Krei JM, M\u00f8ller HJ, Larsen JB. The role of interleukin-18 in the diagnosis and monitoring of hemophagocytic lymphohistiocytosis\/macrophage activation syndrome: a systematic review. Clin Exp Immunol. 2021;203:174\u201382. https:\/\/doi.org\/10.1111\/cei.13543.","journal-title":"Clin Exp Immunol"},{"key":"1621_CR349","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00277-023-05132-6","volume":"102","author":"W Ou","year":"2023","unstructured":"Ou W, et al. Serum cytokine pattern in children with hemophagocytic lymphohistiocytosis. Ann Hematol. 2023;102:729\u201339. https:\/\/doi.org\/10.1007\/s00277-023-05132-6.","journal-title":"Ann Hematol"},{"key":"1621_CR350","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1182\/blood-2017-06-789552","volume":"131","author":"C Girard-Guyonvarc\u2019h","year":"2018","unstructured":"Girard-Guyonvarc\u2019h C, et al. Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice. Blood. 2018;131:1430\u201341. https:\/\/doi.org\/10.1182\/blood-2017-06-789552.","journal-title":"Blood"},{"key":"1621_CR351","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/rheumatology\/kez282","volume":"59","author":"S Yasin","year":"2020","unstructured":"Yasin S, et al. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Rheumatology. 2020;59:361\u20136. https:\/\/doi.org\/10.1093\/rheumatology\/kez282.","journal-title":"Rheumatology"},{"key":"1621_CR352","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/rheumatology\/keq133","volume":"49","author":"M Shimizu","year":"2010","unstructured":"Shimizu M, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology. 2010;49:1645\u201353. https:\/\/doi.org\/10.1093\/rheumatology\/keq133.","journal-title":"Rheumatology"},{"key":"1621_CR353","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cyto.2013.09.007","volume":"65","author":"T Wada","year":"2014","unstructured":"Wada T, et al. Sustained elevation of serum interleukin-18 and its association with hemophagocytic lymphohistiocytosis in XIAP deficiency. Cytokine. 2014;65:74\u20138. https:\/\/doi.org\/10.1016\/j.cyto.2013.09.007.","journal-title":"Cytokine"},{"key":"1621_CR354","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3109\/10428190109097673","volume":"42","author":"H Takada","year":"2001","unstructured":"Takada H, Nomura A, Ohga S, Hara T. Interleukin-18 in hemophagocytic lymphohistiocytosis. Leuk Lymphoma. 2001;42:21\u20138. https:\/\/doi.org\/10.3109\/10428190109097673.","journal-title":"Leuk Lymphoma"},{"key":"1621_CR355","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/rheumatology\/keq133","volume":"49","author":"M Shimizu","year":"2010","unstructured":"Shimizu M, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford). 2010;49:1645\u201353. https:\/\/doi.org\/10.1093\/rheumatology\/keq133.","journal-title":"Rheumatology (Oxford)"},{"key":"1621_CR356","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/jlb.63.6.658","volume":"63","author":"CA Dinarello","year":"1998","unstructured":"Dinarello CA, et al. Overview of interleukin-18: more than an interferon-gamma inducing factor. J Leukoc Biol. 1998;63:658\u201364.","journal-title":"J Leukoc Biol"},{"key":"1621_CR357","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2020.101515","volume":"34","author":"G Griffin","year":"2020","unstructured":"Griffin G, Shenoi S, Hughes GC. Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy. Best Pract Res Clin Rheumatol. 2020;34: 101515. https:\/\/doi.org\/10.1016\/j.berh.2020.101515.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1621_CR358","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.jaip.2018.11.050","volume":"7","author":"KA Risma","year":"2019","unstructured":"Risma KA, Marsh RA. Hemophagocytic lymphohistiocytosis: clinical presentations and diagnosis. J Allergy Clin Immunol Pract. 2019;7:824\u201332. https:\/\/doi.org\/10.1016\/j.jaip.2018.11.050.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1621_CR359","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.semcdb.2015.01.015","volume":"39","author":"S Latour","year":"2015","unstructured":"Latour S, Aguilar C. XIAP deficiency syndrome in humans. Semin Cell Dev Biol. 2015;39:115\u201323. https:\/\/doi.org\/10.1016\/j.semcdb.2015.01.015.","journal-title":"Semin Cell Dev Biol"},{"key":"1621_CR360","doi-asserted-by":"publisher","first-page":"e18503","DOI":"10.1097\/md.0000000000018503","volume":"99","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, et al. Clinical features and outcomes of patients with hemophagocytic lymphohistiocytosis at onset of systemic autoinflammatory disorder and compare with Epstein-Barr virus (EBV)-related hemophagocytic lymphohistiocytosis. Medicine. 2020;99:e18503. https:\/\/doi.org\/10.1097\/md.0000000000018503.","journal-title":"Medicine"},{"key":"1621_CR361","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/cei.13026","volume":"191","author":"M Shimizu","year":"2018","unstructured":"Shimizu M, Inoue N, Mizuta M, Nakagishi Y, Yachie A. Characteristic elevation of soluble TNF receptor II\u202f: I ratio in macrophage activation syndrome with systemic juvenile idiopathic arthritis. Clin Exp Immunol. 2018;191:349\u201355. https:\/\/doi.org\/10.1111\/cei.13026.","journal-title":"Clin Exp Immunol"},{"key":"1621_CR362","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1034\/j.1600-0528.2002.017418.x","volume":"174","author":"H Tsutsui","year":"2000","unstructured":"Tsutsui H, Matsui K, Okamura H, Nakanishi K. Pathophysiological roles of interleukin-18 in inflammatory liver diseases. Immunol Rev. 2000;174:192\u2013209. https:\/\/doi.org\/10.1034\/j.1600-0528.2002.017418.x.","journal-title":"Immunol Rev"},{"key":"1621_CR363","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1182\/blood-2010-01-256099","volume":"116","author":"RA Marsh","year":"2010","unstructured":"Marsh RA, et al. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood. 2010;116:1079\u201382. https:\/\/doi.org\/10.1182\/blood-2010-01-256099.","journal-title":"Blood"},{"key":"1621_CR364","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194369","author":"J Bardet","year":"2021","unstructured":"Bardet J, et al. NLRC4 GOF mutations, a challenging diagnosis from neonatal age to adulthood. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10194369.","journal-title":"J Clin Med"},{"key":"1621_CR365","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/ng.3066","volume":"46","author":"N Romberg","year":"2014","unstructured":"Romberg N, et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet. 2014;46:1135\u20139. https:\/\/doi.org\/10.1038\/ng.3066.","journal-title":"Nat Genet"},{"key":"1621_CR366","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.702527","volume":"12","author":"J Wen","year":"2021","unstructured":"Wen J, et al. Updating the NLRC4 inflammasome: from bacterial infections to autoimmunity and cancer. Front Immunol. 2021;12: 702527. https:\/\/doi.org\/10.3389\/fimmu.2021.702527.","journal-title":"Front Immunol"},{"key":"1621_CR367","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/j.jaci.2016.10.022","volume":"139","author":"SW Canna","year":"2017","unstructured":"Canna SW, et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol. 2017;139:1698\u2013701. https:\/\/doi.org\/10.1016\/j.jaci.2016.10.022.","journal-title":"J Allergy Clin Immunol"},{"key":"1621_CR368","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00289","author":"C Dinarello","year":"2013","unstructured":"Dinarello C, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol. 2013. https:\/\/doi.org\/10.3389\/fimmu.2013.00289.","journal-title":"Front Immunol"},{"key":"1621_CR369","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1073\/pnas.97.3.1190","volume":"97","author":"SH Kim","year":"2000","unstructured":"Kim SH, et al. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci U S A. 2000;97:1190\u20135. https:\/\/doi.org\/10.1073\/pnas.97.3.1190.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1621_CR370","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/s1359-6101(00)00015-0","volume":"12","author":"K Nakanishi","year":"2001","unstructured":"Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 2001;12:53\u201372. https:\/\/doi.org\/10.1016\/s1359-6101(00)00015-0.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1621_CR371","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1006\/bbrc.1999.2064","volume":"267","author":"H M\u00fchl","year":"2000","unstructured":"M\u00fchl H, et al. Interferon-gamma mediates gene expression of IL-18 binding protein in nonleukocytic cells. Biochem Biophys Res Commun. 2000;267:960\u20133. https:\/\/doi.org\/10.1006\/bbrc.1999.2064.","journal-title":"Biochem Biophys Res Commun"},{"key":"1621_CR372","doi-asserted-by":"publisher","first-page":"6088","DOI":"10.1074\/jbc.270.11.6088","volume":"270","author":"A Treumann","year":"1995","unstructured":"Treumann A, Lifely MR, Schneider P, Ferguson MA. Primary structure of CD52. J Biol Chem. 1995;270:6088\u20136088.","journal-title":"J Biol Chem"},{"key":"1621_CR373","first-page":"RA325","volume":"7","author":"A Domaga\u0142a","year":"2001","unstructured":"Domaga\u0142a A, Kurpisz M. CD52 antigen\u2013a review. Med Sci Monit. 2001;7:RA325\u201331.","journal-title":"Med Sci Monit"},{"key":"1621_CR374","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039416","volume":"7","author":"SP Rao","year":"2012","unstructured":"Rao SP, et al. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS ONE. 2012;7: e39416. https:\/\/doi.org\/10.1371\/journal.pone.0039416.","journal-title":"PLoS ONE"},{"key":"1621_CR375","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/ni.2610","volume":"14","author":"E Bandala-Sanchez","year":"2013","unstructured":"Bandala-Sanchez E, et al. T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10. Nat Immunol. 2013;14:741\u20138. https:\/\/doi.org\/10.1038\/ni.2610.","journal-title":"Nat Immunol"},{"key":"1621_CR376","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.578314","volume":"11","author":"NEB Saidu","year":"2020","unstructured":"Saidu NEB, et al. New approaches for the treatment of chronic graft-versus-host disease: current status and future directions. Front Immunol. 2020;11: 578314. https:\/\/doi.org\/10.3389\/fimmu.2020.578314.","journal-title":"Front Immunol"},{"key":"1621_CR377","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.bbmt.2007.09.013","volume":"14","author":"GJ Ruiz-Arg\u00fcelles","year":"2008","unstructured":"Ruiz-Arg\u00fcelles GJ, Gil-Beristain J, Maga\u00f1a M, Ruiz-Delgado GJ. Alemtuzumab-induced resolution of refractory cutaneous chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14:7\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1621_CR378","first-page":"2351","volume":"118","author":"JC Marsh","year":"2011","unstructured":"Marsh JC, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood J Am Soc Hematol. 2011;118:2351\u20137.","journal-title":"Blood J Am Soc Hematol"},{"key":"1621_CR379","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1634\/theoncologist.2007-0218","volume":"13","author":"S Demko","year":"2008","unstructured":"Demko S, Summers J, Keegan P, Pazdur R. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. Oncologist. 2008;13:167\u201374. https:\/\/doi.org\/10.1634\/theoncologist.2007-0218.","journal-title":"Oncologist"},{"key":"1621_CR380","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1756285614563522","volume":"8","author":"E Havrdova","year":"2015","unstructured":"Havrdova E, Horakova D, Kovarova I. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord. 2015;8:31\u201345. https:\/\/doi.org\/10.1177\/1756285614563522.","journal-title":"Ther Adv Neurol Disord"},{"key":"1621_CR381","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s13075-016-1188-6","volume":"18","author":"FA Cooles","year":"2016","unstructured":"Cooles FA, et al. Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies. Arthritis Res Ther. 2016;18:302. https:\/\/doi.org\/10.1186\/s13075-016-1188-6.","journal-title":"Arthritis Res Ther"},{"key":"1621_CR382","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1186\/2047-1440-2-s1-s5","volume":"2","author":"PJ Friend","year":"2013","unstructured":"Friend PJ. Alemtuzumab induction therapy in solid organ transplantation. Transplant Res. 2013;2:S5. https:\/\/doi.org\/10.1186\/2047-1440-2-s1-s5.","journal-title":"Transplant Res"},{"key":"1621_CR383","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s00277-004-0917-0","volume":"83","author":"M Stanglmaier","year":"2004","unstructured":"Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol. 2004;83:634\u201345.","journal-title":"Ann Hematol"},{"key":"1621_CR384","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1365-2567.2009.03115.x","volume":"128","author":"Y Hu","year":"2009","unstructured":"Hu Y, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128:260\u201370.","journal-title":"Immunology"},{"key":"1621_CR385","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1365-2249.1992.tb06421.x","volume":"87","author":"J Crowe","year":"1992","unstructured":"Crowe J, Hall V, Smith M, Cooper H, Tite J. Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material. Clin Exp Immunol. 1992;87:105\u201310.","journal-title":"Clin Exp Immunol"},{"key":"1621_CR386","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/pbc.24188","volume":"60","author":"RA Marsh","year":"2013","unstructured":"Marsh RA, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013;60:101\u20139. https:\/\/doi.org\/10.1002\/pbc.24188.","journal-title":"Pediatr Blood Cancer"},{"key":"1621_CR387","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrclinonc.2010.40","volume":"7","author":"MP Strout","year":"2010","unstructured":"Strout MP, Seropian S, Berliner N. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis. Nat Rev Clin Oncol. 2010;7:415\u201320. https:\/\/doi.org\/10.1038\/nrclinonc.2010.40.","journal-title":"Nat Rev Clin Oncol"},{"key":"1621_CR388","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/RHU.0b013e31824e8d9b","volume":"18","author":"MP Keith","year":"2012","unstructured":"Keith MP, Pitchford C, Bernstein WB. Treatment of hemophagocytic lymphohistiocytosis with alemtuzumab in systemic lupus erythematosus. J Clin Rheumatol. 2012;18:134\u20137. https:\/\/doi.org\/10.1097\/RHU.0b013e31824e8d9b.","journal-title":"J Clin Rheumatol"},{"key":"1621_CR389","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2023.107675","volume":"228","author":"AB O\u0161ep","year":"2023","unstructured":"O\u0161ep AB, Brecl E, \u0160kerget M, Sav\u0161ek L. An unforeseen reality: Hemophagocytic lymphohistiocytosis following alemtuzumab treatment for a multiple sclerosis. Clin Neurol Neurosurg. 2023;228: 107675. https:\/\/doi.org\/10.1016\/j.clineuro.2023.107675.","journal-title":"Clin Neurol Neurosurg"},{"key":"1621_CR390","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","volume":"105","author":"G Pavlasova","year":"2020","unstructured":"Pavlasova G, Mraz M. The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy. Haematologica. 2020;105:1494\u2013506. https:\/\/doi.org\/10.3324\/haematol.2019.243543.","journal-title":"Haematologica"},{"key":"1621_CR391","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/icb.2015.48","volume":"94","author":"L Eon Kuek","year":"2016","unstructured":"Eon Kuek L, Leffler M, Mackay GA, Hulett MD. The MS4A family: counting past 1, 2 and 3. Immunol Cell Biol. 2016;94:11\u201323. https:\/\/doi.org\/10.1038\/icb.2015.48.","journal-title":"Immunol Cell Biol"},{"key":"1621_CR392","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.it.2021.07.002","volume":"42","author":"I Mattiola","year":"2021","unstructured":"Mattiola I, Mantovani A, Locati M. The tetraspan MS4A family in homeostasis, immunity, and disease. Trends Immunol. 2021;42:764\u201381. https:\/\/doi.org\/10.1016\/j.it.2021.07.002.","journal-title":"Trends Immunol"},{"key":"1621_CR393","first-page":"676","volume":"2","author":"P Boross","year":"2012","unstructured":"Boross P, Leusen JH. Mechanisms of action of CD20 antibodies. Am J Cancer Res. 2012;2:676\u201390.","journal-title":"Am J Cancer Res"},{"key":"1621_CR394","doi-asserted-by":"publisher","first-page":"22632","DOI":"10.1074\/jbc.270.38.22632","volume":"270","author":"JP Deans","year":"1995","unstructured":"Deans JP, et al. Association of 75\/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20: evidence against involvement of the cytoplasmic regions of CD20. J Biol Chem. 1995;270:22632\u20138. https:\/\/doi.org\/10.1074\/jbc.270.38.22632.","journal-title":"J Biol Chem"},{"key":"1621_CR395","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","volume":"22","author":"MR Smith","year":"2003","unstructured":"Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359\u201368. https:\/\/doi.org\/10.1038\/sj.onc.1206939.","journal-title":"Oncogene"},{"key":"1621_CR396","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.3389\/fimmu.2017.01902","volume":"8","author":"RA Marsh","year":"2017","unstructured":"Marsh RA. Epstein-Barr virus and hemophagocytic lymphohistiocytosis. Front Immunol. 2017;8:1902. https:\/\/doi.org\/10.3389\/fimmu.2017.01902.","journal-title":"Front Immunol"},{"key":"1621_CR397","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.autrev.2007.02.012","volume":"7","author":"R Dolcetti","year":"2007","unstructured":"Dolcetti R. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders. Autoimmun Rev. 2007;7:96\u2013101. https:\/\/doi.org\/10.1016\/j.autrev.2007.02.012.","journal-title":"Autoimmun Rev"},{"key":"1621_CR398","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nri1201","volume":"3","author":"R K\u00fcppers","year":"2003","unstructured":"K\u00fcppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol. 2003;3:801\u201312. https:\/\/doi.org\/10.1038\/nri1201.","journal-title":"Nat Rev Immunol"},{"key":"1621_CR399","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/emboj\/17.6.1700","volume":"17","author":"E Kilger","year":"1998","unstructured":"Kilger E, Kieser A, Baumann M, Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. Embo j. 1998;17:1700\u20139. https:\/\/doi.org\/10.1093\/emboj\/17.6.1700.","journal-title":"Embo j"},{"key":"1621_CR400","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.virol.2007.10.009","volume":"371","author":"LJ Anderson","year":"2008","unstructured":"Anderson LJ, Longnecker R. An auto-regulatory loop for EBV LMP2A involves activation of Notch. Virology. 2008;371:257\u201366. https:\/\/doi.org\/10.1016\/j.virol.2007.10.009.","journal-title":"Virology"},{"key":"1621_CR401","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.1182\/blood-2007-05-090142","volume":"110","author":"C Mancao","year":"2007","unstructured":"Mancao C, Hammerschmidt W. Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood. 2007;110:3715\u201321. https:\/\/doi.org\/10.1182\/blood-2007-05-090142.","journal-title":"Blood"},{"key":"1621_CR402","doi-asserted-by":"publisher","first-page":"16971","DOI":"10.1074\/jbc.M708459200","volume":"283","author":"CA Walshe","year":"2008","unstructured":"Walshe CA, et al. Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling*. J Biol Chem. 2008;283:16971\u201384. https:\/\/doi.org\/10.1074\/jbc.M708459200.","journal-title":"J Biol Chem"},{"key":"1621_CR403","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1083\/jcb.121.5.1121","volume":"121","author":"JK Bubien","year":"1993","unstructured":"Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol. 1993;121:1121\u201332. https:\/\/doi.org\/10.1083\/jcb.121.5.1121.","journal-title":"J Cell Biol"},{"key":"1621_CR404","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.816098","volume":"8","author":"N Zhang","year":"2021","unstructured":"Zhang N, et al. Epstein-Barr virus and neurological diseases. Front Mol Biosci. 2021;8: 816098. https:\/\/doi.org\/10.3389\/fmolb.2021.816098.","journal-title":"Front Mol Biosci"},{"key":"1621_CR405","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/cr.2015.50","volume":"25","author":"C Ni","year":"2015","unstructured":"Ni C, et al. In-cell infection: a novel pathway for Epstein-Barr virus infection mediated by cell-in-cell structures. Cell Res. 2015;25:785\u2013800. https:\/\/doi.org\/10.1038\/cr.2015.50.","journal-title":"Cell Res"},{"key":"1621_CR406","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nrc1452","volume":"4","author":"LS Young","year":"2004","unstructured":"Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004;4:757\u201368. https:\/\/doi.org\/10.1038\/nrc1452.","journal-title":"Nat Rev Cancer"},{"key":"1621_CR407","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0092-8674(87)90216-9","volume":"50","author":"J Tanner","year":"1987","unstructured":"Tanner J, Weis J, Fearon D, Whang Y, Kieff E. Epstein-Barr virus gp350\/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell. 1987;50:203\u201313. https:\/\/doi.org\/10.1016\/0092-8674(87)90216-9.","journal-title":"Cell"},{"key":"1621_CR408","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1073\/pnas.81.14.4510","volume":"81","author":"JD Fingeroth","year":"1984","unstructured":"Fingeroth JD, et al. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci U S A. 1984;81:4510\u20134. https:\/\/doi.org\/10.1073\/pnas.81.14.4510.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1621_CR409","doi-asserted-by":"publisher","first-page":"16046","DOI":"10.1073\/pnas.1901314116","volume":"116","author":"P Mrozek-Gorska","year":"2019","unstructured":"Mrozek-Gorska P, et al. Epstein-Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection. Proc Natl Acad Sci U S A. 2019;116:16046\u201355. https:\/\/doi.org\/10.1073\/pnas.1901314116.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1621_CR410","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1038\/sj.leu.2402519","volume":"16","author":"AW Langerak","year":"2002","unstructured":"Langerak AW, Moreau E, van Gastel-Mol EJ, van der Burg M, van Dongen JJM. Detection of clonal EBV episomes in lymphoproliferations as a diagnostic tool. Leukemia. 2002;16:1572\u20133. https:\/\/doi.org\/10.1038\/sj.leu.2402519.","journal-title":"Leukemia"},{"key":"1621_CR411","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4103\/jpn.JPN_140_16","volume":"12","author":"B Grzybowski","year":"2017","unstructured":"Grzybowski B, Vishwanath VA. Hemophagocytic lymphohistiocytosis: a diagnostic conundrum. J Pediatr Neurosci. 2017;12:55\u201360. https:\/\/doi.org\/10.4103\/jpn.JPN_140_16.","journal-title":"J Pediatr Neurosci"},{"key":"1621_CR412","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/jbm.S46255","volume":"5","author":"MR George","year":"2014","unstructured":"George MR. Hemophagocytic lymphohistiocytosis: review of etiologies and management. J Blood Med. 2014;5:69\u201386. https:\/\/doi.org\/10.2147\/jbm.S46255.","journal-title":"J Blood Med"},{"key":"1621_CR413","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-021-01220-0","volume":"15","author":"P Guisado-Vasco","year":"2022","unstructured":"Guisado-Vasco P, et al. Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia. J Hematol Oncol. 2022;15:4. https:\/\/doi.org\/10.1186\/s13045-021-01220-0.","journal-title":"J Hematol Oncol"},{"key":"1621_CR414","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1182\/blood-2002-06-1761","volume":"101","author":"MS Cragg","year":"2003","unstructured":"Cragg MS, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101:1045\u201352. https:\/\/doi.org\/10.1182\/blood-2002-06-1761.","journal-title":"Blood"},{"key":"1621_CR415","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1080\/21645515.2018.1508624","volume":"14","author":"JML Casan","year":"2018","unstructured":"Casan JML, Wong J, Northcott MJ, Opat S. Anti-CD20 monoclonal antibodies: reviewing a revolution. Hum Vaccin Immunother. 2018;14:2820\u201341. https:\/\/doi.org\/10.1080\/21645515.2018.1508624.","journal-title":"Hum Vaccin Immunother"},{"key":"1621_CR416","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1038\/s41598-021-82841-w","volume":"11","author":"C Luo","year":"2021","unstructured":"Luo C, et al. Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis. Sci Rep. 2021;11:3255. https:\/\/doi.org\/10.1038\/s41598-021-82841-w.","journal-title":"Sci Rep"},{"key":"1621_CR417","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","volume":"115","author":"E M\u00f6ssner","year":"2010","unstructured":"M\u00f6ssner E, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell\u2013mediated B-cell cytotoxicity. Blood. 2010;115:4393\u2013402. https:\/\/doi.org\/10.1182\/blood-2009-06-225979.","journal-title":"Blood"},{"key":"1621_CR418","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","volume":"6","author":"MD Pescovitz","year":"2006","unstructured":"Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006;6:859\u201366. https:\/\/doi.org\/10.1111\/j.1600-6143.2006.01288.x.","journal-title":"Am J Transplant"},{"key":"1621_CR419","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016596","volume":"6","author":"A Franke","year":"2011","unstructured":"Franke A, Niederfellner GJ, Klein C, Burtscher H. Antibodies against CD20 or B-cell receptor induce similar transcription patterns in human lymphoma cell lines. PLoS ONE. 2011;6: e16596. https:\/\/doi.org\/10.1371\/journal.pone.0016596.","journal-title":"PLoS ONE"},{"key":"1621_CR420","doi-asserted-by":"publisher","first-page":"16971","DOI":"10.1074\/jbc.M708459200","volume":"283","author":"CA Walshe","year":"2008","unstructured":"Walshe CA, et al. Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. J Biol Chem. 2008;283:16971\u201384. https:\/\/doi.org\/10.1074\/jbc.M708459200.","journal-title":"J Biol Chem"},{"key":"1621_CR421","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1182\/blood-2009-08-237537","volume":"115","author":"S Kheirallah","year":"2010","unstructured":"Kheirallah S, et al. Rituximab inhibits B-cell receptor signaling. Blood. 2010;115:985\u201394. https:\/\/doi.org\/10.1182\/blood-2009-08-237537.","journal-title":"Blood"},{"key":"1621_CR422","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jcv.2013.01.016","volume":"57","author":"JL Kroll","year":"2013","unstructured":"Kroll JL, et al. Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes. J Clin Virol. 2013;57:115\u20139. https:\/\/doi.org\/10.1016\/j.jcv.2013.01.016.","journal-title":"J Clin Virol"},{"key":"1621_CR423","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12882-015-0096-3","volume":"16","author":"AJ Hamilton","year":"2015","unstructured":"Hamilton AJ, et al. Autoimmune haemolytic anaemia associated with Epstein Barr virus infection as a severe late complication after kidney transplantation and successful treatment with rituximab: case report. BMC Nephrol. 2015;16:108. https:\/\/doi.org\/10.1186\/s12882-015-0096-3.","journal-title":"BMC Nephrol"},{"key":"1621_CR424","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.crohns.2012.05.002","volume":"7","author":"MP Fitzgerald","year":"2013","unstructured":"Fitzgerald MP, Armstrong L, Hague R, Russell RK. A case of EBV driven haemophagocytic lymphohistiocytosis complicating a teenage Crohn\u2019s disease patient on azathioprine, successfully treated with rituximab. J Crohns Colitis. 2013;7:314\u20137. https:\/\/doi.org\/10.1016\/j.crohns.2012.05.002.","journal-title":"J Crohns Colitis"},{"key":"1621_CR425","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.cmi.2015.02.002","volume":"21","author":"R San-Juan","year":"2015","unstructured":"San-Juan R, et al. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe: Results of the ESGICH Questionnaire-based Cross-sectional Survey. Clin Microbiol Infect. 2015;21:604\u20139. https:\/\/doi.org\/10.1016\/j.cmi.2015.02.002.","journal-title":"Clin Microbiol Infect"},{"key":"1621_CR426","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10060197","author":"JS Pagano","year":"2018","unstructured":"Pagano JS, Whitehurst CB, Andrei G. Antiviral drugs for EBV. Cancers. 2018. https:\/\/doi.org\/10.3390\/cancers10060197.","journal-title":"Cancers"},{"key":"1621_CR427","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41409-019-0699-6","volume":"55","author":"N Stocker","year":"2020","unstructured":"Stocker N, et al. Pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes. Bone Marrow Transplant. 2020;55:586\u201394. https:\/\/doi.org\/10.1038\/s41409-019-0699-6.","journal-title":"Bone Marrow Transplant"},{"key":"1621_CR428","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/bjh.12386","volume":"162","author":"D Chellapandian","year":"2013","unstructured":"Chellapandian D, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol. 2013;162:376\u201382. https:\/\/doi.org\/10.1111\/bjh.12386.","journal-title":"Br J Haematol"},{"key":"1621_CR429","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/508387","volume":"2015","author":"O Al Asad","year":"2015","unstructured":"Al Asad O, et al. Alternative therapy for epstein-barr virus related hemophagocytic lymphohistiocytosis. Case Rep Oncol Med. 2015;2015: 508387. https:\/\/doi.org\/10.1155\/2015\/508387.","journal-title":"Case Rep Oncol Med"},{"key":"1621_CR430","first-page":"42","volume":"7","author":"K Goudarzipour","year":"2013","unstructured":"Goudarzipour K, Kajiyazdi M, Mahdaviyani A. Epstein-barr virus-induced hemophagocytic lymphohistiocytosis. Int J Hematol Oncol Stem Cell Res. 2013;7:42\u20135.","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"1621_CR431","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2008-01-135160","volume":"112","author":"V Minard-Colin","year":"2008","unstructured":"Minard-Colin V, et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood. 2008;112:1205\u201313. https:\/\/doi.org\/10.1182\/blood-2008-01-135160.","journal-title":"Blood"},{"key":"1621_CR432","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3389\/fonc.2019.00713","volume":"9","author":"C Shannon-Lowe","year":"2019","unstructured":"Shannon-Lowe C, Rickinson A. The global landscape of EBV-associated tumors. Front Oncol. 2019;9:713. https:\/\/doi.org\/10.3389\/fonc.2019.00713.","journal-title":"Front Oncol"},{"key":"1621_CR433","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/978-981-10-7230-7_21","volume":"1045","author":"H Kimura","year":"2018","unstructured":"Kimura H. EBV in T-\/NK-Cell tumorigenesis. Adv Exp Med Biol. 2018;1045:459\u201375. https:\/\/doi.org\/10.1007\/978-981-10-7230-7_21.","journal-title":"Adv Exp Med Biol"},{"key":"1621_CR434","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fimmu.2019.00146","volume":"10","author":"MHM Barros","year":"2019","unstructured":"Barros MHM, Vera-Lozada G, Segges P, Hassan R, Niedobitek G. Revisiting the tissue microenvironment of infectious mononucleosis: identification of EBV infection in T cells and deep characterization of immune profiles. Front Immunol. 2019;10:146. https:\/\/doi.org\/10.3389\/fimmu.2019.00146.","journal-title":"Front Immunol"},{"key":"1621_CR435","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/bjh.15988","volume":"186","author":"Y Song","year":"2019","unstructured":"Song Y, Wang Y, Wang Z. Requirement for etoposide in the initial treatment of Epstein-Barr virus\u2013associated haemophagocytic lymphohistiocytosis. Br J Haematol. 2019;186:717\u201323. https:\/\/doi.org\/10.1111\/bjh.15988.","journal-title":"Br J Haematol"},{"key":"1621_CR436","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/bjh.17638","volume":"196","author":"NK El-Mallawany","year":"2022","unstructured":"El-Mallawany NK, Curry CV, Allen CE. Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes. Br J Haematol. 2022;196:31\u201344. https:\/\/doi.org\/10.1111\/bjh.17638.","journal-title":"Br J Haematol"},{"key":"1621_CR437","doi-asserted-by":"publisher","first-page":"8605274","DOI":"10.1155\/2016\/8605274","volume":"2016","author":"EJ Sch\u00e4fer","year":"2016","unstructured":"Sch\u00e4fer EJ, Jung W, Korsten P. Combination immunosuppressive therapy including rituximab for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adult-onset still\u2019s disease. Case Reports in Rheumatology. 2016;2016:8605274. https:\/\/doi.org\/10.1155\/2016\/8605274.","journal-title":"Case Reports in Rheumatology"},{"key":"1621_CR438","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.7150\/ijbs.60114","volume":"17","author":"H Zheng","year":"2021","unstructured":"Zheng H, et al. New insights into the important roles of tumor cell-intrinsic PD-1. Int J Biol Sci. 2021;17:2537\u201347. https:\/\/doi.org\/10.7150\/ijbs.60114.","journal-title":"Int J Biol Sci"},{"key":"1621_CR439","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18:153\u201367. https:\/\/doi.org\/10.1038\/nri.2017.108.","journal-title":"Nat Rev Immunol"},{"key":"1621_CR440","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1006\/geno.1994.1562","volume":"23","author":"T Shinohara","year":"1994","unstructured":"Shinohara T, Taniwaki M, Ishida Y, Kawaichi M, Honjo T. Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics. 1994;23:704\u20136.","journal-title":"Genomics"},{"key":"1621_CR441","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","volume":"173","author":"JM Chemnitz","year":"2004","unstructured":"Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004;173:945\u201354.","journal-title":"J Immunol"},{"key":"1621_CR442","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/intimm\/dxm057","volume":"19","author":"T Okazaki","year":"2007","unstructured":"Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19:813\u201324. https:\/\/doi.org\/10.1093\/intimm\/dxm057.","journal-title":"Int Immunol"},{"key":"1621_CR443","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd2712","author":"N Patsoukis","year":"2020","unstructured":"Patsoukis N, Wang Q, Strauss L, Boussiotis VA. Revisiting the PD-1 pathway. Sci Adv. 2020. https:\/\/doi.org\/10.1126\/sciadv.abd2712.","journal-title":"Sci Adv"},{"key":"1621_CR444","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1007\/s00018-020-03737-y","volume":"78","author":"Z Chi","year":"2021","unstructured":"Chi Z, Lu Y, Yang Y, Li B, Lu P. Transcriptional and epigenetic regulation of PD-1 expression. Cell Mol Life Sci. 2021;78:3239\u201346. https:\/\/doi.org\/10.1007\/s00018-020-03737-y.","journal-title":"Cell Mol Life Sci"},{"key":"1621_CR445","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"key":"1621_CR446","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.2147\/ott.S105862","volume":"9","author":"X Wang","year":"2016","unstructured":"Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016;9:5023\u201339. https:\/\/doi.org\/10.2147\/ott.S105862.","journal-title":"Onco Targets Ther"},{"key":"1621_CR447","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nature04444","volume":"439","author":"DL Barber","year":"2006","unstructured":"Barber DL, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682\u20137.","journal-title":"Nature"},{"key":"1621_CR448","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-024-01557-2","volume":"17","author":"F Zhou","year":"2024","unstructured":"Zhou F, et al. PD-1 blockade immunotherapy as a successful rescue treatment for disseminated adenovirus infection after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2024;17:34. https:\/\/doi.org\/10.1186\/s13045-024-01557-2.","journal-title":"J Hematol Oncol"},{"key":"1621_CR449","doi-asserted-by":"publisher","first-page":"e30298","DOI":"10.1097\/md.0000000000030298","volume":"101","author":"Y Pi","year":"2022","unstructured":"Pi Y, Wang J, Wang Z. Massive pericardial effusion due to chronic active Epstein-Barr virus infection successfully treated with PD-1 blockade: a case report. Medicine. 2022;101:e30298. https:\/\/doi.org\/10.1097\/md.0000000000030298.","journal-title":"Medicine"},{"key":"1621_CR450","doi-asserted-by":"publisher","first-page":"1093719","DOI":"10.3389\/fimmu.2023.1093719","volume":"14","author":"Y Ma","year":"2023","unstructured":"Ma Y, et al. Outcomes of programmed death protein-1 inhibitors treatment of chronic active Epstein Barr virus infection: a single center retrospective analysis. Front Immunol. 2023;14:1093719. https:\/\/doi.org\/10.3389\/fimmu.2023.1093719.","journal-title":"Front Immunol"},{"issue":"796","key":"1621_CR451","doi-asserted-by":"publisher","first-page":"e797","DOI":"10.1016\/j.cmi.2023.01.017","volume":"29","author":"Y Song","year":"2023","unstructured":"Song Y, et al. PD-1 blockade and lenalidomide combination therapy for chronic active Epstein-Barr virus infection. Clin Microbiol Infect. 2023;29(796):e797-796.e713. https:\/\/doi.org\/10.1016\/j.cmi.2023.01.017.","journal-title":"Clin Microbiol Infect"},{"key":"1621_CR452","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1182\/blood.2019003886","volume":"135","author":"P Liu","year":"2020","unstructured":"Liu P, et al. Nivolumab treatment of relapsed\/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults. Blood. 2020;135:826\u201333. https:\/\/doi.org\/10.1182\/blood.2019003886.","journal-title":"Blood"},{"key":"1621_CR453","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s13023-023-02861-9","volume":"18","author":"R Chen","year":"2023","unstructured":"Chen R, et al. Sintilimab treatment for chronic active Epstein-Barr virus infection and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children. Orphanet J Rare Dis. 2023;18:297. https:\/\/doi.org\/10.1186\/s13023-023-02861-9.","journal-title":"Orphanet J Rare Dis"},{"key":"1621_CR454","doi-asserted-by":"publisher","first-page":"466","DOI":"10.22034\/iji.2023.99254.2629","volume":"20","author":"M Zhu","year":"2023","unstructured":"Zhu M, et al. Rescue of HLH with T and B lymphocyte involvement due to Epstein-Barr virus by PD-1 inhibitor\/ruxolitinib and rituximab combination regimens: a case report. Iran J Immunol. 2023;20:466\u201372. https:\/\/doi.org\/10.22034\/iji.2023.99254.2629.","journal-title":"Iran J Immunol"},{"key":"1621_CR455","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1007\/s00277-023-05476-z","volume":"102","author":"Y Xu","year":"2023","unstructured":"Xu Y, Li W, Gan J, He X, Huang X. An analysis of sintilimab combined with ruxolitinib as compassionate therapy for 12 adults with EBV-associated hemophagocytic lymphohistiocytosis. Ann Hematol. 2023;102:3325\u201333. https:\/\/doi.org\/10.1007\/s00277-023-05476-z.","journal-title":"Ann Hematol"},{"key":"1621_CR456","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.2147\/idr.S372998","volume":"15","author":"Y Pi","year":"2022","unstructured":"Pi Y, Wang J, Wang Z. Successful treatment of relapsed Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis after allo-HSCT with PD-1 Blockade: a case report. Infect Drug Resist. 2022;15:3751\u20136. https:\/\/doi.org\/10.2147\/idr.S372998.","journal-title":"Infect Drug Resist"},{"key":"1621_CR457","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40425-018-0365-3","volume":"6","author":"M Sadaat","year":"2018","unstructured":"Sadaat M, Jang S. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report. J Immunother Cancer. 2018;6:49. https:\/\/doi.org\/10.1186\/s40425-018-0365-3.","journal-title":"J Immunother Cancer"},{"key":"1621_CR458","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/annonc\/mdx113","volume":"28","author":"D Shah","year":"2017","unstructured":"Shah D, Shrestha R, Ramlal R, Hatton J, Saeed H. Pembrolizumab associated hemophagocytic lymphohistiocytosis. Ann Oncol. 2017;28:1403.","journal-title":"Ann Oncol"},{"key":"1621_CR459","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ejca.2018.01.063","volume":"93","author":"I Satzger","year":"2018","unstructured":"Satzger I, et al. Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab. Eur J Cancer. 2018;93:150\u20133.","journal-title":"Eur J Cancer"},{"key":"1621_CR460","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/annonc\/mdw537","volume":"28","author":"M Takeshita","year":"2017","unstructured":"Takeshita M, Anai S, Mishima S, Inoue K. Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression. Ann Oncol. 2017;28:186\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdw537.","journal-title":"Ann Oncol"},{"key":"1621_CR461","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1212\/wnl.0000000000005420","volume":"90","author":"M Saarela","year":"2018","unstructured":"Saarela M, et al. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. Neurology. 2018;90:849\u201351. https:\/\/doi.org\/10.1212\/wnl.0000000000005420.","journal-title":"Neurology"},{"key":"1621_CR462","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.2147\/idr.S441460","volume":"17","author":"L Chen","year":"2024","unstructured":"Chen L, Wang J, Wang Z. PD-1 blockade-induced hemophagocytic lymphohistiocytosis, a dilemma therapeutic outcome in 2 patients with CAEBV: a case series. Infect Drug Resist. 2024;17:1545\u201350. https:\/\/doi.org\/10.2147\/idr.S441460.","journal-title":"Infect Drug Resist"},{"key":"1621_CR463","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.cmi.2021.08.015","volume":"27","author":"XJ Xu","year":"2021","unstructured":"Xu XJ, Zhao FY, Tang YM. Fulminant cytokine release syndrome in a paediatric patient with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis receiving nivolumab treatment. Clin Microbiol Infect. 2021;27:1710\u20132. https:\/\/doi.org\/10.1016\/j.cmi.2021.08.015.","journal-title":"Clin Microbiol Infect"},{"key":"1621_CR464","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025077","author":"JI Henter","year":"2024","unstructured":"Henter JI, et al. Diagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisited. Blood. 2024. https:\/\/doi.org\/10.1182\/blood.2024025077.","journal-title":"Blood"},{"key":"1621_CR465","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00277-020-04083-6","volume":"99","author":"SE Yoon","year":"2020","unstructured":"Yoon SE, et al. A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study. Ann Hematol. 2020;99:2095\u2013104. https:\/\/doi.org\/10.1007\/s00277-020-04083-6.","journal-title":"Ann Hematol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01621-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-024-01621-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01621-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T07:05:22Z","timestamp":1730963122000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-024-01621-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":465,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1621"],"URL":"https:\/\/doi.org\/10.1186\/s13045-024-01621-x","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"assertion":[{"value":"11 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}